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Every baby, child and adolescent will experience pain at times throughout their life. 
Despite its ubiquity, pain is a major challenge for individuals, families, healthcare 
professionals, and societies. Pain is often hidden and can go undiscussed or 
ignored. Undertreated, unrecognised, or poorly managed pain in childhood leads to 
important and long-lasting negative consequences that continue into adulthood. This 
undertreatment should not continue. We have the tools, expertise, and evidence to 
provide better treatment for childhood pain.   
 
In this Commission we present four transformative goals that will, if achieved, 
transform the lives of children with pain and their families. These goals, taken at face 
value, may seem simple and obvious. However, if the goals were easy to achieve 
there would be few, if any, young people reporting poorly managed acute pain, pain 
after surgery or procedures, or ongoing chronic pain. Pain is multifactorial, and 
influenced by biological, psychological and social factors, making it complex and 
difficult to treat effectively, especially in infants, children and adolescents. This 
Commission focusses on children from birth through to 24 years of age in developed 
countries.  
 
The first transformative goal is to ‘make pain matter’. Here we argue that pain has 
not mattered enough, as evidenced by common failings in clinical practice, low levels 
of training and investment, and a lack of concern for issues of equity and equality. 
Despite some good examples of knowledge translation, we highlight that investment 
in a strong social science research base for paediatric pain will catapult us into a 
new era in which we can address the social and cultural context of pain. 
 
The second is to ‘make pain understood’ at a fundamental biological and 
psychological level. There has been excellent progress in mechanistic 
understandings of nociception and pain perception for both acute and chronic pain 
states but gaps in knowledge remain. Advances in developmental biology, in 
genetics, in psychology, and in nosology and classification will all help speed up the 
discovery in these areas. There is also a need for greater investment in larger 
international birth cohort studies that incorporate comprehensive pain-related 
measurement incorporated. 
 
The third is to ‘make pain visible’. Pain can and should be assessed. We need to 
help improve understanding of optimal methods for pain assessment at throughout 
childhood and in all clinical scenarios. While subjective pain report is the primary and 
desirable method when this is possible, many of the methods and measures that are 
in common use can and should be improved. There has been development in 
understanding the biological correlates of pain, and in broader patient reported 
outcome variables that can expand our horizons. Finally, we should be more 
focussed on assessing outcomes that are important to patients, rather than those 
that are central to researchers and clinicians.  
 
The fourth is to ‘make pain better’ by advancing our knowledge of multiple treatment 
options in all areas. There is a very small number of randomised controlled trials of 
pain interventions in children. The pipeline for innovation and novel treatments is 




treatment options. There is innovation in new ways to personalise individual 
treatments, but there is a need for greater investment in research and coordinated 
approaches at all levels. 
 
This Commission is a call for researchers, clinicians, policy makers, funders, and 
healthcare executives to engage enthusiastically and deliver both the easy and the 








Pain is a feature of life that is present across cultures and age.1-3 It is often associated with 
acute injury or is a symptom of disease, but it can also be evoked by physical activities or 
social interactions: from play and sport to body adornment and religious ritual. Regardless of 
its origin, pain is typically experienced as unpleasant, negative, and threatening. While a 
primary function of acute pain is to protect an organism from potential damage, at a biological, 
psychological and social level it also functions to promote recovery, to facilitate escape from 
immediate harm, to avoid future harm, and to warn others of potential danger. 4 Nevertheless, 
pain can often extend past its functional utility, and can exist only as a negative experience. 
Despite the ubiquity of pain, it remains poorly understood in infants, children and adolescents, 
and has made relatively few leaps since Jill Lawson’s advocacy in 1986 led to change in the 
use of anaesthesia in infants (Box 1). Approaching 40 years later, we consider how much of 
what we do (or fail to do) now for children in pain will come to be seen as unwise, unacceptable 
or unethical in another 40 years? Indeed, how much of our common practice and received 
wisdom should policy makers, funders, researchers or clinicians challenge? How much of what 
is being done can and should be built upon and strengthened? We think in many areas of 
paediatric pain that it is time for change. In this commission we considered four transformative 
goals that we believe will improve the treatment of paediatric pain. Our goals are simple, but 
delivering them is complex and needs multidisciplinary attention from researchers, clinicians, 
policy makers, funders and the public. Our goals are not sequential, but the aim of this 
commission is to (1) make pain matter, (2) make pain understood, (3) make pain visible, and 
(4) make pain better. 
 
Box 1. Jeffrey and Jill Lawson and advocacy for pain management 
 
Here, we consider children of all ages, from infants to late adolescents, and focus this 
Commission on how middle to high income countries can improve their provision of pain 
treatment. We need to adopt the best pain management practices when we treat children who 
experience all types of pain, from routine inoculation to cancer pain management, to the 
provision of complex residential multidisciplinary rehabilitation for idiopathic disabling pain. 
Beyond the individual we also demonstrate how we can better understand the interpersonal 
and social challenges of under-recognised pain-related distress. Childhood pain is common, 
ranging from acute to chronic, and includes procedural, disease-related, and breakthrough 
pain amongst others (see Figure 1). We highlight the effects of childhood pain on parents and 
other significant family members, and the challenge of explaining pain to those around us, 
including other children.  As with all illness, disease and distress, pain also operates on a 
moral and social plane10 and any attempt to improve paediatric pain management would be 
incomplete without consideration of the linguistic construction of the meaning of pain, and how 
this impacts the recognition of pain in others and equity in access to care. 
 
Figure 1. Common types of pain during childhood 
 
Goal 1: Make pain matter 
When one is in severe pain, nothing is as important as finding relief. But pain in others evokes 
a less urgent response. Pain is often expected to be transitory, diagnostically useful, bearable 
and easily forgotten, but when this is not the case it is more difficult to tolerate. While people 
can often be highly sensitive to their own pain, a social insensitivity to pain in others is 
common11, 12, and when people describe their pain the importance of it can be too easily 
diminished.13 Here, we outline a strategy to make children’s pain matter to others. To achieve 
this there needs to be an understanding of the social science of pain. We will discuss how the 
absence of voice can lead to an assumption that there is an absence of need and we will give 
examples of how pain can be inadvertently dismissed as being unimportant, and how our 
language can suggest to children that pain should be stoically and quietly endured 14-16. We 
will consider how ignoring childhood pain can be prevented in children who have a more 




greater needs. We will also consider how best to avoid scenarios where analgesia is withheld 
or withdrawn during clinical treatments. Importantly, we appreciate that these goals will only 
be achieved when a clear organisational strategy is in place. Successful approaches which 
have been used to improve knowledge, attitudes and practices in health care and other formal 
settings frequented by children will be discussed.  
 
Social organisation 
Access to pain relief should be a basic human right, but navigating policy and governmental 
responses to uphold that right has not been easy and is arguably in retreat.17 Pain is not 
immediately thought to be a social phenomenon, but more often considered to be a physical 
and cognitive experience. Nevertheless, culture influences our behavioural expression of pain, 
how others view people experiencing pain and one’s response to someone in pain.18 We learn 
how to express and respond to noxious stimuli in keeping with societal norms from our families 
and those around us in society, and phrases such as ‘big boys don’t cry’, and ‘no pain no gain’ 
are common. For many, the experience of pain is short and self-limiting (e.g. pain following an 
acute injury) or relatively straightforward to treat, with a known underlying aetiology. Therefore, 
for many in society, pain that does not follow an acute trajectory can be dismissed and 
perceived as unimportant because of the belief that all pain is similar to the acute pain that 
most people experience. However, this is not true, and these societal misconceptions of pain 
can be harmful. Dominant social beliefs that pain is temporary and should be endured can 
result in stigmatization of children and adolescents living with chronic pain.19 It can also 
predispose infants, children, and adolescents to endure repeated procedural pain,20 and can 
then lead to a culture of poor pain management practice.21, 22 Variability in the experience and 
expression of pain may be a further contributing factor to dominant misconceptions and myths 
held in society that inhibit access to pain management. 
 
Traditionally nurses and physicians were not formally taught about pain, nor how to provide 
adequate pain care to treat infants, children and adolescents who had to undergo painful 
procedures and treatments (e.g. lumbar puncture, bloodwork, burn dressing changes). In fact, 
clinicians were more concerned about the adverse consequences of treating pain (e.g. 
administration of opioids) than the consequences of inflicting pain.23-25 Medical education in 
pain remains a challenge. Veterinary students receive more formal education on pain (e.g. 
understanding pain, pain treatment) than nursing and medical students.26 Improvements in 
education are needed but alone are inadequate as even when individual clinicians are 
interested in improving their own practice, systematic barriers exist.27 
 
The experience of pain within healthcare is often a product of treatment. For example, 
vaccinations and other related skin-breaking needle procedures (e.g. bloodwork, intravenous 
cannulas) are routine and represent a substantial number of painful procedures in healthcare 
settings for paediatric patients, yet in many cases pain relief is infrequently given.20 For 
example, in the UK, children are usually given 16 separate injections between birth and 14 
years, many without any pain management 28. While the short-term pain associated with these 
procedures could be considered fleeting or inconsequential, they are known to cause 
considerable distress when repeated in children or infants over weeks, months or years, when 
each momentary experience is compounded and can be traumatic.29 Untreated pain has 
multiple consequences. For example, the establishment or exacerbation of needle fear is 
common during childhood, where 20-50% of adolescents report fear of needles.30 This 
consequence matters: it can delay or prevent important vaccinations and blood tests that are 
necessary for the prevention or diagnosis of illness. For example, needle fear and phobias 
were found to be the deterrent in obtaining the influenza vaccine as adults working in a 
healthcare setting with 8% of clinicians and 27% of hospital employees not receiving their flu 
vaccine due to needle fear.30 What is often presented as ‘just one poke’ has long lasting 
effects.31 Moreover, not actively treating procedural pain is not defendable as there is high-
quality evidence on how to reduce pain during procedures including needle skin puncture for 




recommendations, which reviewed the evidence for reducing pain during immunization in 
children.32 The WHO guideline specifically described the importance of, and how to, reduce 
pain at the time of vaccination (Box 2). The evidence is clear that providing pain management 
needs to be as essential as any other component of medical procedures and treatments (e.g. 
sterility, explaining the procedure to children and caregivers). 
 
Box 2: Vaccination pain management: from clinical practice guideline to WHO 
 
Despite international guidelines, even in the most highly resourced medical centres, a culture 
of assertive pain management is not always common.20, 34  Whilst there are places that 
implement institutional wide interventions to manage needle pain, so children and adolescents 
receive better procedural pain care35, this practice is not widespread. Interestingly, pain 
management can differ between sexes. For example, pain management is more commonly 
offered to infant boys than girls, and parental presence influences its provision.36 In early 
childhood, boys are more likely to be prescribed opioids, but in adolescence girls are more 
likely to be prescribed opioids37. However, girls are also more likely to report chronic pain 
during adolescence compared to boys. 
 
It is not solely pain treatment that can differ by sex. Despite girls being more likely to report 
chronic pain during adolescence, their chronic pain concerns were dismissed significantly 
more often by physicians (35%) compared to boys (17%) 38. Similar bias towards pain 
management differences has been found to persist into adulthood in most but not all studies 
39 and describe as an ethical issue in pain care 40. 
 
Mobilising knowledge; Dissemination and implementation  
The problems of poor paediatric pain practice may stem from lack of knowledge or 
understanding, or from a failure of training. However, this is at best a partial view. The problem 
in many cases is not one of knowledge but of knowledge translation, which refers to the uptake 
and application of knowledge in practice with a focus on overcoming barriers. This is also often 
referred to as knowledge mobilization, or increasingly, dissemination and implementation of 
evidence to improve practice.9 Shortening this gap from knowledge production to 
implementation 41 is critical and might now be more achievable given the explosion in new 
computerised media. Consumers of healthcare can access this information much more 
readily, and there is increasing pressure for scientists to consider the translation and impact 
of their research. This means, making their research understandable for the lay person and 
seeing how it can change knowledge or behaviour. Of course, there is also a flood of poor-
quality, non-evidence-based information on the Internet regarding pain, and researchers can 
be nervous to disseminate to the public, for good reasons. Strategies to tackle misinformation 
and provide a trusted accessible place to access new evidence-based information could be 
one way to disseminate. Because of the need for reliable information and support, and now 
the technological possibility to provide it there are a growing number of initiatives to 
disseminate science more quickly to parents, healthcare professionals, and communities.  
 
One such prominent organisation – Solutions for Kids in Pain (SKIP), launched in 2019 brings 
together Canada’s paediatric pain knowledge producers, front-line knowledge user 
organizations, end beneficiaries, and over 100 partners from across sectors. SKIP’s four goals 
to support its mission and vision are: 1) Confirm knowledge user needs (including patients, 
caregivers, health professionals, administrators, policy makers) and organize current 
resources and evidence; 2) Produce and promote knowledge mobilization tools to address 
diverse knowledge user needs; 3) Facilitate institutional change by assisting knowledge users 
to access, adapt, and implement evidence; and 4) Increase awareness and foster a sense of 
urgency amongst the general public to prevent and treat pain in children. SKIP’s long-term 
outcome is improved children’s pain management in Canadian health institutions, beginning 





Good examples also exist of how to collectively capture and benchmark practice. The 
‘EUROPAIN’ (EUROpean Pain Audit In Neonates) study is one example in neonatal care 
showing widespread analgesic practice but with extensive unexplained variability between 
sites.42 With older children there are also examples; in Australia the Paediatric Electronic 
Persistent Pain Outcomes Collaboration (PaedePPOC) initiative introducing common 
assessment practice for pain management in 10 centres has successfully been integrated into 
practice, providing the means for comparison between populations and different resource 
settings.43 
 
Although some countries have not developed surveillance and benchmarking practices for 
paediatric pain management,44 there have been substantial advances.  Where evidence-
based guidance is available, the focus should turn to its implementation, where successful 
attempts at translating knowledge into practice have been demonstrated.45 There is no single 
correct approach to implementing an organisation change programme to improve pain care. 
35, 46-48 It is worth stressing that pain management also often occurs outside of the hospital, in 
the home 49 in educational settings,50 in the community (e.g., family practitioners offices), and 
in pre-hospital emergency environments.51 No single strategy works in all settings, and context 
needs to be considered; thus type of institution, leadership, culture, value of research in 
practice, number and type of healthcare professionals, and physical resources52 are all 
relevant and need to be considered. A further example at a hospital level is the implementation 
of the “Children’s Comfort Promise” which executed new protocols for nurses to provide 
options to reduce pain during needle procedures.35 One prominent international initiative 
called ChildKind (http://childkindinternational.org/). Uniquely, ChildKind is an attempt to 
establish and maintain practice improvement through certification, developed by the Special 
Interest Group on Pain in Children of the International Association for the Study of Pain. The 
core principles include 1) Presence of a facility wide policy on pain prevention, assessment, 
and treatment which demonstrates clear institutional commitment to pain relief; 2) Ongoing 
education on pain for staff, trainees, and patients; 3) Evidence of the sustained use of 
developmentally appropriate process for pain assessment; 4) Specific evidence informed 
protocols for pain prevention and treatment including pharmacological, psychological, and 
physical methods; 5) Regular institutional self-monitoring within the framework of continuous 
quality improvement. 
 
Finally, a final example is the online initiative ‘#ItDoesn’tHaveToHurt’ which involved a 
collaboration between paediatric pain researchers, parents, and ‘YummyMummyClub.ca’, a 
digital platform for Canadian parents to provide evidence-based information about children’s 
pain management across social media platforms (e.g., Facebook, YouTube, Instagram, 
Twitter). This initiative had more than 72 million content views worldwide in just one year.9 
(https://cihr-irsc.gc.ca/e/49821.html). Examples are summarised in Table 1.  
 
Table 1. Recent and ongoing initiatives to mobilise knowledge in paediatric pain 
 
Equity 
Focus on the delivery and provision of care should come with a focus on equity. Equity is not 
about equal access to shared resource, but rather fair access to unequal resources according 
to need. Worldwide there is poor equity in access to pharmacological pain management,53 and 
the types of multidisciplinary treatment described in this Commission are not available for all 
infants, children, and adolescents. Despite the documented inter- and intra-national 
inequalities, there is little formal study of equity and inequity in the context of pain, with some 
exceptions,54 but very few in paediatrics. In research there has traditionally been an interest 
in income, racial and gender driven inequities. With children the most extensive study of this 
has been in sickle cell disease, an inherited chronic disorder of blood cells causing painful 
‘crises’ in sufferers who are mostly of African heritage and in whom prejudicial inequity in 
access to pain management is well recognised.55, 56 Other forms of pain management inequity 




have their postoperative pain assessed less often and receive fewer opioids and fewer days 
of opioid pain management for the same surgery as children and adolescents without 
disability.57 It is concerning that children with disabilities receive less pain management but 
also experience the most pain.58 There is a need to better understand the patterns and impact 
of inequity in pain provision at a societal level. There is also a need to explore the 
psychological effects of perceived inequity. In human experimental studies, for example, we 
are beginning to understand that perceptions of injustice and inequity can affect pain and 
disability status. If one believes they are being unfairly treated this can worsen both the 
experience of pain, disability and treatment effectiveness.59, 60 We know so little about how 
young people and their parents perceive inequity and injustice, and there are few studies 
attempting to implement change in perception, reality, or both.  
 
An examination of the social science of paediatric pain treatment would be incomplete without 
recognition that pain management has become highly politicised in many countries due to the 
changes in patterns of opioid prescribing and use for chronic pain, and the subsequent 
increase in substance use disorders and related harms.61 This debate has also been extended 
to the appropriate use of opioids in acute pain and in paediatric anaesthesia 62. Eighty percent 
of the world’s supply of opioid medicines is distributed to less than 10% of the world’s 
population with the highest supply being in the USA and Canada, followed by Austria and 
Germany.63, 64 Paediatric pain medicine, however, has not been explicitly addressed in most 
of the national responses to the different ‘opioid crises’ leading to a concern that measures to 
control opioid use in adult pain management will be inappropriately applied to young people.65, 
66 In policy and in the media portrayal of the North American opioid crisis conflates substance 
use disorders and pain medication. An analysis of the Canadian media reports that the 
negative sequela of opioids is frequently reported whereas an understanding of how to treat 
acute and chronic pain is not.67 Through this media, public views have been influenced to 
consider opioids as drugs of addiction rather than pain medicine. This has in turn, influenced 
policy approaches (e.g. criminalization, significant oversight of physician prescribing 
behaviour), which risk distancing physicians from treating those who need their care.68 Health 
care professionals, young people and parents continue to hold misconceptions and believe 
myths about opioid use in paediatric patients69 in which the media paints the opioids 
themselves as the villain and underlying reason for substance misuse. Opioids have their 
place in paediatric pain medicine. In a context of the oversupply of opioids, childhood pain can 
usefully be considered a risk factor for long-term harmful exposure to opioids.70 
 
Overall, we need a new social science of pain and explicit recognition that at an individual and 
societal level, articulation of pain will always have to struggle against forces that would silence 
it. For some questions we need a political science of pain to take us beyond description and 
policy toward understanding how political values shape experience. Other questions will need 
novel anthropology to help understand culturally embedded experience, and we need modern 
implementation science to explore the best evidence for organisational change.  
 
Research and clinical priorities to make pain matter 
Three areas should be prioritised that will enable us to achieve our goal to make pain matter 
to everyone; 1) Improve equity; 2) mitigate stigma, and 3) understand the social science of 
pain, including sociology, social psychology, political science, and anthropology (Box 3). A 
final area on improving accountability in all sectors of society, increasing awareness, urgency, 
and responsibility for all children’s pain needs to be addressed by funders and policy makers 
(see Box 10).  
 
Box 3: Research and clinical priorities to make pain matter 
 
First, we need to understand equity and inequity in pain management, and where inequity lies 
within our healthcare systems. Within chronic pain particularly, much of the research is 




are most likely to be treated by Caucasian males. Less is known about how different cultures, 
races, and socioeconomic groups interpret and communicate pain, or their preferences for 
pain management. When pain becomes invisible to others, in particular to those with power 
and control over the allocation of shared resource then inequality and inequity are perhaps 
inevitable. Such inequities pervade paediatric pain management. And where there is invisibility 
and inequity, there is the opportunity for unchallenged prejudicial inequality. We need to 
address whose pain matters least, and the social forces that silence the dissent or attempts 
at social or political redress. 
 
Second we need to research the optimal methods for managing stigma and mitigate its effects. 
Pain has become a means to enable the medical gaze in modern medicine, relevant only 
insofar as it is diagnostically useful.71 Pain that is without diagnostic meaning becomes 
‘idiopathic’, ‘medically unexplained’, ‘functional’, or ‘psychological’. Patients and families often 
report these labels as unhelpful or insulting but socially they function to silence complaint; pain 
doesn’t seem to ‘matter’.72, 73 Medical professionals may not be able to diagnose a specific 
disease or have immediate tools to provide pain relief. Whilst it is possible to inform the patient 
that they ‘don’t know’ what is wrong, this must be communicated appropriately. When pain is 
dismissed, families report significant distress from attempting to talk about something people 
do not want to hear. But to not talk about something so fundamental as your child’s pain is 
equally distressing. 
 
Finally, we need to invest in a social science of paediatric pain. Starting from the idea that pain 
is inherently subjective, and that culturally “it lends itself to invisibility and is language 
resistant”.14 Like all private mental events each person has a privileged position from which to 
observe one’s own experience, meaning that others’ experience of one’s pain is always 
secondary, always dependent on the clarity and force of the signal; upon the ability of the 
observer to be able to decode the signal,18 and their aptitude for allocentricism, and ultimately 
empathy.74 Further, part of how humans cope with life events, with the sometimes staggering 
levels of social and personal injustice, multiple experiences of loss, and fear of one’s own 
inevitable death, is to have inherent biases toward optimism, avoidance of emotional distress, 
and systematic diminution of the impact of problems that are difficult or impossible to solve.75 
For the pain of others these self-protection biases translate into the systematic 
underestimation of the pain children experience. Pain underestimation is not mitigated by 
familiarity, it is not a stranger effect: mothers underestimate the pain of their children and 
nurses of their patients.76 We have the capacity to experientially avoid distress, including the 
distress caused by witnessing other’s unalterable suffering.77 Socially and psychologically, 
every day and in multiple ways, we turn away from the suffering of others.  
 
Goal 2. Make pain understood  
Improvements in the care of children with pain, including better recognition, valid explanation, 
reliable assessment and the development of safe and effective treatments, will only emerge 
in a safe and sustainable way if informed by a full scientific understanding of pain. Our second 
goal is to make childhood pain understood by improving our fundamental knowledge of the 
developmental aspects of nociception and pain systems. 
 
Moving on from Descartes 
Central to the challenge of explaining mechanisms in pain is the stubborn persistence of a 
longstanding Cartesian ‘dualism’ regarding the relationship between physical and mental 
events that can hamper more modern scientific inquiry.78, 79 Particularly damaging is the 
stubborn belief that an individual’s pain can only be objectively investigated by, and even 
reduced to its purely ‘biological’ drivers thereby denying the psychological and social elements 
that impact the experience of all types of pain.80-85 We judge that it is important to be clear in 




to understand or explain pain as a whole. This is particularly pertinent in children’s pain where 
both mechanisms and perceptions are also a function of age and state of development. 
 
To make pain understood, in all its contexts, we should be consistent in our use of pain 
terminology, which can seem complex and confusing, not least because it requires frequent 
revision with advancing knowledge and experience. Some of the current most widely used 
clinical and scientific definitions and classifications of pain are described in Box 5.  In this 
discussion of mechanisms we have used the general clinical terms acute and chronic pain, as 
defined, nevertheless acknowledging that each encompasses an overlapping range of causes 
and mechanisms making a strict temporal distinction somewhat arbitrary and artificial. 
 
For chronic pain the International Association for the Study of Pain (IASP) reported the results 
of their task force on an updated classification in 2020, and following the latest version of the 
WHO International Classification of Diseases (ICD-11) included chronic pain as a discrete 
entity for the first time.86 Although the appearance of a new classification and nomenclature 
for chronic pain is itself a major success story, bringing increasing awareness and clarity to a 
complex area, it may not best represent all types of chronic pain in children: both acute and 
chronic pain in paediatric practice should also always be considered in a developmental 
context. 
 
Box 4. Pain definition and classifications 
 
Nociception, and somatosensory pain transmission 
Figure 2 presents a schematic of current knowledge regarding the different mechanisms for 
nociceptive, neuropathic and nociplastic pain (defined in Box 4) illustrating how they relate to 
different sources of pain, and showing some of the basic neural circuits and pathways that 
lead to pain perception in the brain. Clearly, one or more somatosensory mechanism may be 
involved in a given clinical pain presentation, and this may change over time. For example, 
due to disease progression in a long-term health condition such as arthritis or cancer, or when   
pain arises or persists although damage to tissue cannot be identified.  A common 
characteristic of pain transmission by any mechanism is that modulation of pain signalling can 
potentially occur at multiple sites along pain pathways including peripheral pain receptors 
(nociceptors), the spinal cord, brainstem and importantly the brain, which is also integrating 
multiple other pain and non-pain related inputs, leading to different patterns of activity that 
characterise an individual’s pain. Importantly, during childhood virtually all body systems are 
changing structurally and functionally, including pain processing mechanisms themselves, 
potentially influencing almost every aspect of the experience of pain at different ages with 
ongoing consequences for later life.  
 
Figure 2 Pain mechanisms and sources of pain 
 
Nociceptive pain occurs within an intact and normally functioning somatosensory nervous 
system and can therefore be regarded to an extent as ‘normal pain’ because it is the 
mechanism of the common everyday pain we experience after injury. It is often predictable in 
duration and intensity and is by far the most common and frequent experience reported. 
Therefore, but often erroneously, nociceptive pain is assumed to be the ‘model’ for all pain. 
The physiology, pharmacology and psychology of nociceptive pain differs at different ages. 
This, and its relationship to other pain mechanisms and states needs to be fully appreciated 
in order to understand the mechanisms of aberrant or refractory pain presentations; including 
those underlying the intensity, quality, persistence and consequence of pain.   
 
Developmental aspects of nociception and analgesia 
Nociceptive pain mechanisms have been studied in children but there remain considerable 
and important gaps in our knowledge. Nociceptive pain involves temporary structural and 




(i.e., peripheral and central sensitisation leading to lower pain thresholds (allodynia) and 
increased sensitivity to previously painful stimuli (hyperalgesia) at the site of inflammation or 
trauma, and changes affecting more distant sites). This neuroplasticity determines the 
adaptive ability of the somatosensory nervous system, and the mechanisms that initiate and 
control it have proven important for our understanding of the changes in nociception 
throughout development and the changes in normal and pathological pain states in children 
and adults.88, 89 
 
Nociceptive signals are known to be processed through complex networks of neurons, glia 
and immune cells in the peripheral and central nervous system. Pain perception, rather than 
being confined to a discreet single brain area (as with many senses such as hearing or vision), 
is the result of activation of a distributed network of brain regions that signal and modulate the 
sensory, affective, motivational and cognitive aspects of pain (Figure 2). Activity in this 
distributed network, sometimes described as the pain ‘neuromatrix’, gives rise to spatial and 
temporal patterns of activity in the brain known as the ‘dynamic pain connectome’ that 
characterise pain by recruiting multiple brain regions to produce a constantly adjusting 
signature of pain that is currently not well characterised during different stages of 
development.90-92 Nevertheless, even newborn infants, who are just a few days old, show 
adult-like patterns of noxious-evoked brain activity following nociceptive events that adults 
would describe as mildly painful.93, 94 
 
Central and peripheral nervous system responses to nociceptive stimuli are clearly evident 
after birth.  However, the rate of functional maturation varies in different regions of the nervous 
system and so there are marked differences in the response to pain at different ages. In the 
mature somatosensory nervous system nociceptors respond to mechanical, thermal and/or 
chemical stimuli and transduce signals into action potentials transmitted by primary afferent 
fibres to the spinal cord; the first central nervous system site for modulation and integration of 
noxious and other incoming sensory information (Figure 2). Ascending pathways from spinal 
laminae I and V project to brain regions sub-serving the different aspects of pain perception 
including stimulus location, intensity and modality, and those involved in modulation, and the 
regions associated with physiological and behavioural responses to pain (Figure 3). 
Descending pathways from the brainstem have a bimodal function and can inhibit or facilitate 
spinal cord signalling. 
 
Figure 3 Brain networks in nociceptive (acute) and chronic pain 
 
Following birth, noxious-evoked brain activity can be evaluated using electroencephalography 
(EEG), or inferred from blood flow changes using near-infrared spectroscopy, and functional 
magnetic resonance imaging (fMRI). Cortical responses are evoked by noxious events such 
as heel lance in preterm (from 25 weeks post-conception) and term neonates,97, 98 
immunization in infants,99 and venous cannulation in young children.100 The pattern and 
distribution of EEG response and relationship to stimulus intensity differs according to 
postnatal age and sex, and is influenced by stress, illness and previous experience even at 
this young age. In neonates and adults, fMRI shows activation of brain regions known to be 
involved in both sensory and affective components of pain response94 and variation with 
stimulus modality and intensity.101 These data highlight the potential for developing central 
nociceptive pathways to be influenced by pain inputs, and can provide a proxy for measuring 
effects of analgesia.97  Laboratory and clinical studies have already identified many age-
dependent changes in these nociceptive processing pathways that influence responses to 
noxious stimuli, tissue injury and analgesia. For example, alterations in the function, 
distribution and density of key receptors involved in the detection and transmission of 
nociceptive signals influences the sensitivity of the system.102, 103 Myelination influences the 
latency of response.  These, and other differences, result in a marked change in the 
relationship between stimulus intensity and response that vary with age (e.g., mechanical 




nociceptive reflex responses such as hind-limb withdrawal105 and abdominal musculature 
contraction106 are very low in preterm neonates and increase with postnatal age. In addition, 
responses are initially more generalised and less discriminate, with specificity for a nociceptive 
stimulus improving with increasing postnatal age.105 
 
In healthy populations of children, cross-sectional107 and longitudinal108, 109 psychophysical 
studies have shown that increases in (modality specific) pain thresholds continue throughout 
adolescence, also with differences between males and females emerging for some. Similar to 
adults,110 responses to standardized experimental stimuli also show significant between-
subject variability. The balance between excitatory and inhibitory descending modulation of 
incoming pain signals is known to differ in immature nociceptive circuits; reduced endogenous 
inhibitory control also contributing to the lower thresholds and more generalised reflex 
responses at younger ages.111, 112 Low threshold sensory input (such as touch), and 
spontaneous movements, contribute to activity-dependent normal maturation of sensori-motor 
circuits in the spinal cord.113, 114 In the brain, spontaneous and evoked patterns of activity in 
the somatosensory cortex are also influenced by postnatal age and type of injury.92, 115  
 
Sensitisation and long-term effects 
Alongside lower nociceptive thresholds at younger ages, tissue injury is known to induce 
sensitisation, familiar to us as the tissue sensitivity that develops for some time after a 
significant injury, at all ages including neonates and infants. This is demonstrated by reduced 
mechanical thresholds for the hind-limb withdrawal reflex following repeated heel lance116 and 
similarly, reductions in the force of mechanical stimulus required to evoke contraction of 
abdominal muscles (i.e. abdominal skin reflex) has quantified changes in wound sensitivity 
following abdominal surgery117 and referred visceral hyperalgesia in infants with unilateral 
hydronephrosis of the kidney.106 However, different forms of tissue damage (e.g. inflammation, 
surgical injury, visceral stimuli, nerve injury, chemotherapy) also have age-dependent 
mechanisms that influence the patterns of behavioural sensitivity that are observed.118-121 In 
normal circumstances, these changes in pain modulation leading to sensitisation of the system 
resolve with healing, but in a proportion of patients this does not happen for reasons that are 
less clear but are starting to be investigated. Persistence of sensitisation is thought to be a 
key feature of many types of chronic pain. A better understanding of the initiating and 
maintaining factors for sensitisation during development will shed further light on why some 
pain is more refractory to treatment may open pathways to potentially new therapies.  
 
Therefore, how an individual responds to and experiences pain is different throughout infancy, 
childhood and adolescence, and this difference is also influenced by the cause of the pain, 
and related psychological, environmental and other factors including pain duration, intensity, 
and age first experienced; strongly reinforcing the assertion that children are not just little 
adults. 
 
Perhaps unsurprisingly, reflecting the differences in underlying mechanisms, the 
developmental pharmacodynamic profile of analgesic interventions, such as opioids, can also 
be influenced by age, sex, genetics and the type of tissue injury.122-124 Morphine, for example,  
is widely used to manage distress and pain during mechanical ventilation of very preterm 
infants in neonatal intensive care42, with uncertainty regarding subtle long-term effects of 
treatment. The importance of pharmacogenomic influences in neonates is relatively 
unexplored, however, genetic variations that affect drug clearance (e.g., uridine 5′-diphospho-
glucuronosyltransferase enzyme, UGT1A9) or response (e.g., catechol-o-methyl transferase, 
COMT) can result in greater morphine exposure in the brain. This, together with neonatal 
clinical factors, are differentially related to anxiety and depressive symptoms (internalizing) 
and to acting out (externalizing) behaviours at 18 months postmenstrual age in children born 
very preterm.125 Aside from these genetic influences it is also clear that throughout the lifespan 




females; for this reason laboratory studies increasingly include sex as a biological variable,123, 
126, 127 but these potentially important factors are rarely addressed in clinical studies. 
 
Long-term consequences of acute pain 
Activity-dependent regulation renders the developing nervous system vulnerable to injury-
induced changes in structure and function that can alter future development and therefore 
responses including those to re-injury throughout the lifespan.111, 127, 128 In infants and children, 
neuroimaging studies have identified long-term changes in structure and connectivity that 
correlate with the degree of acute pain exposure during neonatal intensive care unit (NICU) 
management following preterm birth, and with subsequent cognitive, behavioural and 
somatosensory outcomes in later life.109, 129, 130 Alterations in somatosensory function in 
adolescents who experienced neonatal intensive care early in life have also been clearly 
demonstrated; but precise changes can vary, depending on initial exposure (e.g. gestational 
age at birth, need for surgery, duration of intensive care), type and intensity of experimental 
stimulus, and age at follow-up.131 
 
The degree to which persistent changes in somatosensory function correlate with altered 
response to future injury as shown in laboratory studies 127 or risk of chronic pain in later life 
is far from fully understood and requires further clinical evaluation. Complex age-dependent 
differences in communication between multiple physiological systems are likely to be relevant, 
for example, in juvenile rodent pain models spinal neuro-glial interactions have been 
associated with enhanced response to re-injury following neonatal incision127 and also with 
delayed emergence of allodynia, a marker of sensitisation, following traumatic nerve injury.118 
 
Chronic pain 
Pain that persists is sometimes challenging to explain mechanistically and can be very difficult 
to manage clinically.132 Chronic pain lasting for longer than 3 months, or beyond the expected 
time of healing following an injury, encompasses a wide range of potential antecedents, 
symptoms, mechanisms, and diagnoses. The biopsychosocial model of pain is helpful to fully 
appreciate and understand antecedents to chronic pain, the mechanisms involved and how to 
best assess and treat pain.133  Data from adult neuroimaging and other studies have shown 
changes in brain structure, function and neurochemistry associated with transition from acute 
to chronic pain that include a general shift away from brain regions encoding the sensory 
components of pain towards those such as the subcortical limbic system, amygdala and 
hippocampus that encode motivational and emotional aspects; this maps well with features 
seen in clinical presentations of both adults and children with chronic pain (Figure 3).134, 135 
Comparisons with healthy individuals, and some evidence of reversal of brain changes with 
effective treatment of chronic pain, also imply that the observed changes could be implicated 
in both the cause and effect of on-going pain; it’s important to note that data do not support 
any attempt to dichotomise chronic pain to either ‘physical’ or ‘psychological’ in its origins, and 
to do so is both inaccurate and unhelpful.135, 136 The study of chronic pain in children lags 
woefully behind that in the adult despite data suggesting that it too is a serious global health 
and economic problem the full impact of which is likely yet to be fully uncovered.137-139  
 
Although the incidence of chronic pain in childhood has been documented,140 integrative 
research examining mechanisms contributing to pain remains limited, and even less examined 
is the role of childhood chronic pain on later biological development and health.  Acute pain in 
children can progress to chronic pain, potentially leading or predisposing to chronic pain and 
other chronic health problems as adults.141, 142  
 
There are substantial gaps in our current understanding of the transition from acute to chronic 
pain in children and the maintenance of pain; initial data imply that multiple antecedents, 
mechanisms and other factors are likely to be interacting. Data on the importance of 
psychosocial and pre-morbid risk factors such as psychiatric conditions, depression, anxiety, 




conditions including postsurgical pain, with biological factors, including female sex and 
nociceptive function clearly also relevant 143-145. Using the example of adolescent 
endometriosis-related pelvic pain, Figure 4 attempts to model and summarise some of the 
many different factors that likely contribute to the development and maintenance of chronic 
pain 146. The concept of groups of ‘inductors’ of pain and ‘resilience’ factors (due to disease 
and an individual’s predisposition) that will interact to determine the clinical features and 
measurable changes in psychophysical and brain structural and functional parameters are 
key. Although many of the potentially important contributors are common to patients of all 
ages, the superimposition of developmental processes on these factors will determine 
differences seen at different ages: some examples are discussed below.  
 
Figure 4. Potential Mechanisms Contributing to susceptibility to Paediatric Chronic Pain 
 
Developmental nociceptive plasticity 
Importantly, throughout development, there are ‘critical periods’ when neurobiological factors 
and a wide range of experiences interact to shape normal brain development and long-term 
behaviour.113, 148 Areas for simpler stimulus-dependent responses develop early, while 
integration of key regulatory centres such as the thalamus149 and the structure, function and 
connections of regions for more advanced evaluation mature at older ages.91 Developmental 
processes such as neurogenesis and apoptosis, migration of neurons to appropriate targets, 
formation of synapses, gliogenesis and myelination occur throughout the late prenatal period 
but continue after birth, with activity-dependent processes further refining synaptic function 
and neural circuit formation in the postnatal period and beyond. However, this normal 
developmental trajectory may be disrupted by abnormal stimulus exposures (e.g., persistent 
pain input at critical times).  Prolonged exposure to acute nociceptive pain and episodes of 
high pain intensity may trigger adverse neuroplastic changes as previously mentioned in 
neonates who experienced admission to a NICU. Psychophysical evaluation of 
somatosensory function with quantitative sensory testing (QST) has identified persistent 
changes associated with prior experience or chronic disease in children that were previously 
poorly recognised.(128) Diabetic neuropathy causing neuropathic pain is thought to be rare in 
children, but it was found that almost half of teenagers with Type 1 diabetes had detectable 
subclinical changes in small-fibre function.150 Following childhood acute lymphatic leukaemia, 
deficits in vibration and mechanical detection thresholds likely reflect persistent 
chemotherapy-induced neuropathy.151 Persistent sensory loss (anaesthesia) and/or sensory 
gain (allodynia) has been identified adjacent to scars many years following surgery in the 
neonatal period109 and later childhood.152, 153 Nerve injury in early life does not result in 
neuropathic pain as frequently in younger children as if a similar injury occurred in an adult, 
but in laboratory models pain may emerge in later life, long after any injury has taken place 
and thought to heal.118 This highlights the potential for clinical presentations in childhood to 
differ from that seen at older ages, despite the same initial insult and for subtle changes, 
possibly predisposing to long term pain, to go undetected.  
 
Endogenous modulation  
Disruption in normal endogenous descending controls from the brain is considered a factor 
important in adults with many persistent pain states. Further understanding of the development 
of inhibitory modulation, alterations induced by different pain conditions, and interactions with 
psychological factors at different ages may improve understanding of the transition to chronic 
pain in children, provide targets for therapy, and help to monitor progress.154  Psychophysical 
testing using conditioned pain modulation (CPM) protocols evaluate the degree and 
directionality (facilitatory or inhibitory) of descending modulation from the brainstem by 
measuring changes in sensitivity to a test stimulus before and after a conditioning stimulus at 
a distant body site: decreased sensitivity to the test stimulus indicates descending inhibition, 
whereas increased sensitivity indicates descending facilitation.155 An increased degree of 
inhibitory CPM has been reported in older children aged 12-17 years versus those 8-11 




seen in juvenile rodent studies (128); but results are also influenced by CPM protocol.157, 158 
In children with functional abdominal pain, both decreased descending inhibition and 
generalized increased pressure sensitivity on testing suggest centrally driven changes leading 
to enhanced responses to nociceptive inputs 159. Similarly, children with high levels of pain 
and dysfunction related to functional abdominal pain continued with persistent pain and 
increased central sensitization (temporal summation to heat stimulus) years later into 
adulthood.160 Impaired CPM predicts persistent post-surgical pain in adults,161 and while 
impaired inhibition was identified in 49% of adolescents with chronic pain associated with 
idiopathic scoliosis,162 more research is needed in paediatric populations to clarify its 
significance.  However, reduced inhibition did predict the transition from acute to persistent 
musculoskeletal pain in children.145 Similarly, offset analgesia (OA) protocols in which 
endogenous inhibition of pain is induced (Figure 4) also potentially allow exploration of pain 
inhibitory mechanisms that, although conceptually related to CPM, likely act via different pain 
pathways and have been little used so far in children 163, 164.  
 
Phenotypical sensory profiling 
One of the major advances in adult chronic pain has been in the exploration of individual 
somatosensory function (sensory phenotyping) again using QST.165, 166 Sensory abnormalities 
appear in different combinations in different patients who have similar pain symptoms 
suggesting that no single biological mechanism readily explains the various patterns of 
sensory dysfunctions observed.(166)  In adults, patterns of increased or decreased sensitivity 
have identified specific sensory profiles (sensory loss, mechanical hyperalgesia, thermal 
hyperalgesia) that may provide greater mechanistic insight than disease-based 
classifications.167, 168 In children with chronic pain further standardised evaluation in much 
larger samples will be required to both fully characterise somatosensory alterations associated 
with chronic pain, and evaluate the potential use of sensory profiling as biomarkers for 
prediction of persistent pain, indicators of mechanism or the response to treatment. In addition, 
evaluations of the interplay between psychosocial variables (e.g., fear of pain, anxiety, 
depression, and worry associated with pain) and QST-assessed nociceptive function may also 
be helpful to predict pain outcomes in youth at-risk for the development of chronic pain.169, 170 
 
The brain and non-neural CNS structures  
Compared with literature in adults, relatively few paediatric chronic pain studies have included 
neuroimaging. Those available have predominantly included adolescents with complex 
regional pain syndrome (CRPS), a poorly understood but relatively common presentation in 
children’s chronic pain clinics. Nevertheless, findings have included: i) alterations in brain 
structure and connectivity171 that may differ in acute versus chronic states, and from adults 
with CRPS172 ii) different patterns and degrees of brain activation in response to sensory 
stimuli applied to affected and unaffected CRPS limbs136 iii) reduced gray matter density in 
thalamic reticular nucleus associated with increased pain intensity,172 and altered brain 
connectivity within the amygdala, salience default mode and sensorimotor networks173 iv) 
associations with functional outcome (e.g. fear of pain 174, and v) improvement in symptoms 
and at least partial reversal of brain changes following intensive physical rehabilitation.171, 175, 
176  
 
There is no doubt that recent technical developments of bespoke brain imaging methodologies 
that are specifically designed for the neonatal and paediatric population will advance 
understanding of the cerebral processes that underlie the development of paediatric pain.177, 
178  Alterations in thalamic function and thalamocortical dysrhythmia, that may influence the 
intensity and perception of persistent pain have been observed in adults179, 180 and shifts from 
sensorimotor to emotion-related circuitry134 as previously indicated have been associated with 
the transition from acute to chronic pain. Connectivity changes within the dorsal medial 
prefrontal cortex-amygdala-accumbens circuit as well as smaller amygdala volume were risk 
factors for persistence of back pain in adults.181 Neuroimaging has not yet been utilised to 





The roles of non-neural glial cells in the nervous system extend well beyond homeostasis, 
formation of myelin, and support for neurones and have been implicated in the maintenance 
and modulation of chronic neuropathic pain (Box 4; Figure 2) throughout postnatal 
development and into adulthood. Microglia have critical effects on neurogenesis, synaptic 
pruning and synaptic plasticity.182, 183 The normal age- and sex-dependent developmental 
trajectories of microglial distribution and function can be influenced by afferent input and 
environmental factors.111, 183-185 Subsequent immune or environmental challenges, and 
physical or psychological stressors can influence susceptibility to neurological and 
psychological disorders186-189 or more specifically influence injury response and analgesic 
efficacy.122, 127 
 
Stress and environment 
A popular target for exploring potential mechanisms underlying pathophysiological recovery 
and environmental factors contributing to chronic pain are those that relate to stress responses 
in the context of threat, and their relationship with measures of resilience.190, 191 Acute stress 
alters modulation of experimental nociceptive pain sensitivity in healthy adults (e.g. changes 
in temporal summation, reduced inhibitory CPM and hyperalgesia), increases anxiety, and 
may be variably associated with changes in other physiological parameters (e.g. differences 
in blood pressure or cortisol).171, 192-194 Chronic stress, on the other hand, is highly comorbid 
with chronic pain populations.195 Interestingly, chronic stress has been categorized as a 
“worldwide epidemic” by the World Health Organization: it has been associated with increased 
rates of mental illness and suicide, and costs over 300 billion US dollars annually.196, 197 
 
Physiological stress can alter nociceptive responses from very early life. Noxious-evoked brain 
activity recorded using EEG in response to heel lance was increased in term-born neonates 
with higher cortisol.198 Whereas, in an investigation of the long-term effect of severe stress 
exposure in the neonatal period, acute performance-related stress did not reduce sensitivity 
to experimental stimuli (e.g., thermal and pressure tolerance) in children who had previously 
experienced severe burn injury as neonates unlike healthy control children.199 
 
The experience of adverse and stressful life events in childhood may also be related to the 
maintenance and exacerbation of chronic pain in later life; but identifying stress as a causal 
factor is complicated by variable results in different studies and populations.200-202 Children 
exposed to environmental stressors or early adverse life events may have higher risk for 
cognitive, emotional, and health problems,203, 204 but the timing, severity, and type of stress 
needed to induce this cycle and how it may contribute to chronic pain is unclear. For example, 
negative life events in early childhood have been variably reported to be predictive205 or have 
no association206 with functional abdominal pain in adolescents.  
 
Conversely, the Biological Reactivity Model posits that stress may be protective for some, 
although the required level is unknown.207 Nevertheless, translational models of deprivation, 
threat/stress, drug exposure and injury during early life demonstrate significant adverse and 
persistent effects on brain structure, behavioural outcome, hypothalamic-pituitary-adrenal 
(HPA) axis function, response to re-injury and risk of medical and psychiatric disorders in later 
life.97, 208-212 In contrast, ‘positive experiences’ (environmental enrichment/parental 
care/healthy diet) can improve outcome in laboratory models of early life stress;  effects vary 
with age and sex and further demonstrate the complexity and overlap of mechanisms involved 
in stress response, pain perception, and mood.209 
 
Numerous environmental factors may be important in regulating long-term pain responses. 
The gut microbiome, for example, influences visceral sensitivity, either directly or via 
alterations in stress response and has been implicated in chronic gastrointestinal disorders in 
both children and adults.213, 214 A range of organisms colonize the gut from birth, with variability 




brain axis with immune, neural, endocrine and metabolic pathways that alter 
neurodevelopmental and behavioural outcomes such as anxiety and fear learning.209 
Approaches to studying multiple, interacting physiological systems and molecular pathways 
are needed for the development of translatable biomarkers that would facilitate the study of 
stress responses, resilience, and vulnerability across both human and animal studies across 
the age spectrum.  
 
Genetic influences 
Genetic factors are estimated to account for 20-55% of reported variability in experimental 
pain sensitivity,215 and influence the risk of transition from acute to chronic pain.132 Single 
nucleotide polymorphisms in multiple genes have been associated with a number of different 
chronic pain conditions.216, 217 As previously mentioned, pharmacogenomic differences may 
be relevant as they can also influence response to current analgesic medications218 and 
potentially new analgesic targets based on genetically determined differences in molecular 
signalling in individuals with chronic pain have been identified.219 
 
Genetic disorders can also more directly result in neuropathic pain. Mutations affecting 
voltage-gated sodium (Nav) channels on sensory nerves that can influence pain sensitivity 
and/or be associated with specific pain disorders are increasingly recognised in children.220 
Erythromelalgia (a rare disease characterised by neuropathic pain typically experienced in the 
hands and feet) related to mutations of the SCN9A gene that alter excitability of Nav1.7 
channels, produces severe pain and the genotype influences both the age of onset and the 
pharmacological response to potential analgesic interventions.221 Neuropathic pain is often 
the first presentation of Fabry disease, a lysosomal storage disease, and as this is an X-linked 
disorder, pain tends to occur earlier and can be more severe in boys than girls; enzyme 
replacement therapy may reduce the pain and improve long-term outcome.222-224 
 
Epigenetic modifications in DNA structure and chromatin formation regulate gene expression 
in early development, and in response to environmental cues, and may be transmitted across 
generations.225 Interactions between genes and the environment have been associated with 
early life (perinatal and postnatal) events that adversely210, 226 or positively227 influence 
neurodevelopment, and account for a large proportion of individual variance in risk for chronic 
disease over the lifespan 227. Epigenetic mechanisms also play roles in the development or 
maintenance of persistent pain228, 229 and may offer potential analgesic targets if more specific 
agents are developed.230. How pain risk genes manifest phenotypically in differing 
environments will be an important area of inquiry. Additionally, investigation of 
intergenerational pain transmission231-233 will be a valuable contribution to the field. Advances 
in genetic testing and more detailed phenotyping of clinical pain conditions may improve 
individualised therapy.219  
 
We are making slow progress understanding how the maturing pain system determines and 
influences both current and future pain states. In Box 5 we summarise the main priorities for 
further investigation in this area and changes in research and clinical practice that should be 
employed to make childhood pain more understood. 
 
Box 5: Research and clinical priorities to make pain understood 
 
Research and clinical priorities to make pain understood. 
First, for pain to matter, it must be correctly understood. When an experience is ubiquitous it 
can be misinterpreted as unimportant. With procedural pain being common, and prevalence 
estimates for chronic and recurrent pain estimated at approximately 28%,140 it is tempting to 
re-classify pain as a normal part of life. But when it comes to child pain: common does not 
mean trivial. Such high prevalence rates, however, do beg an explanation, should give us 
pause to ask whether we are always talking about the same thing when we talk about pain. 




and clinical practice in chronic pain, but expect its application in the next decade. Masked 
behind high prevalence rates reported in epidemiology is a complex network of inter-related 
functions and dysfunctions of the pain system. Making that system understood is a primary 
goal. We encourage further debate on the definition of pain. In some fields, constant 
redefinition is considered indecision, but in pain we believe that this definition needs to be 
regularly questioned, work managed by a task force of the International Association for the 
Study of Pain who published the latest definition of pain in 2020 87. Further, classification of 
disease states characterised by pain should be further developed.  
 
Second, a major challenge in making pain understood is to escape the shadow of a pervasive 
dualism that diverts and misdirects science. An example is the search for an objective 
measure of pain as a goal in itself which inappropriately relegates private experience as 
inaccurate or of less value than a biological correlate.83, 84 It is possible to better define 
biological correlates and surrogates which will be helpful, but pain should also be defined 
within a psychological and social context, as well as a developmental context. A related 
example is the practice of representing pain as only a sensory phenomenon, measuring 
intensity and ignoring affect, cognition, motivation, or behaviour. Escaping dualistic notions of 
subjective and objective, of mind and body, of physiology and psychology is not easy. These 
inside (hidden) – outside (observable) distinctions are coded in language, structure much of 
how we experience the world,234 and are useful in many areas of science and practice.  
However, they are not useful in the study of pain science and they hold us back. 
 
Third, perhaps the biggest advance in paediatric pain science in the last 20 years has been in 
developmental biology. Early experience of pain matters and has a lasting effect on nervous 
system development and subsequent pain behaviour. However, there is still a long way to go 
in understanding the impact of developmental factors on nociception, pain, child anxiety, and 
their clinical assessment and treatment. 
 
Fourth, further methods are needed in order to facilitate pain assessment in neonates that are 
rigorous, valid, and reliable. It is unacceptable to be ignorant of anyone’s pain in the 21st 
Century, particularly those who are most vulnerable. 
 
Fifth, mechanisms underlying the development of chronic pain is an important area of study 
where better understanding is needed. First, focussing on mechanism we can now better 
describe pathology in peripheral and central nervous system function. Tissue damage can 
invoke peripheral sensitisation, but different forms of damage have age-specific responses. 
For some types of chronic pain repeated peripheral sensitisation is thought to be a key feature. 
However, we do not know how important persistent peripheral sensitisation is for the onset 
and persistence of chronic pain. Indeed, a major turning point in this field will be to understand 
and treat the risk factors of developing chronic pain after an acute injury.  Multiple mechanisms 
are implicated in the development of different chronic pain presentations, including central 
nervous system vulnerabilities which project into adulthood.131 Higher depressive 
symptomology, anxiety, and adverse life events are implicated in the transition between acute 
and chronic pain. Understanding the long-term effects of often short exposures to physical 
insult at critical stages of development is imperative. Advances in human neuroimaging 
techniques will undoubtedly help172 as will investment in the development of biomarkers and 
better phenotyping. This science is still in its infancy and improvements in measurement, in 
identification, and in replication are all necessary to better understand pain and its 
mechanisms. 
 
Finally, investment in longitudinal datasets must continue and be developed, as these provide 
unique and critical information over the course of childhood and adolescence. There are very 
few registries of children with pain. The advances in other areas of paediatrics, from rare 
disease to trauma registries show how transformational these can be. Although life-long 




Longitudinal Study of Parents and Children (ALSPAC) cohort in the UK,236, 237 we also need to 
invest in clinical cohorts of well described painful diseases. These registries can be helpful in 
phenotyping and understanding the impact of indirect influences of environmental stress and 
of family context. However, these databases are rare, and their absence is setting us back in 
our understanding. Although there are some databases, these are not specifically medical or 
pain-related databases, but rather general developmental databases assessing a wide range 
of data on everything from road safety to diet. Pain researchers and clinicians should have a 
more prominent role when setting up these databases, as pain is a common feature not only 
of a healthy childhood, but also disease. Assessing pain in these databases is critical for 
properly understanding its advancement and impact on childhood.  
 
Goal 3:  Make pain visible.  
Childhood pain can be assessed, no matter the age or clinical status of the child. Children 
need the opportunity to communicate their pain to clinicians, parents, and caregivers to drive 
decision making regarding treatment options and to assess whether a treatment is efficacious. 
Nevertheless, there are challenges, especially in the youngest patients, and in patients with 
intellectual, communication, or motor limitations. However, methods are available and should 
be used. Pain should be made visible by performing a developmentally appropriate valid pain 
assessment in every child. 
 
Pain assessment in children is an inferential process in which all available information about 
the child should be considered. This is not an easy endeavour as, by definition, pain is a 
private mental experience. While the gold standard is self-report, whereby the child directly 
describes their experiences, this is not always possible and other indirect measures including 
facial expression, behavioural observations, physiological responses, such as changes in 
heart rate or respiratory rate, and neuroimaging approaches can also be used to examine this 
private experience. Nevertheless, in most cases human language provides a rich channel by 
which subtle sensory and affective experiences can be communicated, and early in 
development children learn to verbalize their experiences. This is not different for pain, and 
expressions such as “ouch” are used to describe and communicate pain to others.  
 
Assessing pain 
In clinical practice, the most commonly used pain assessment is a numerical rating scale.238 
This approach requires children to attend internally, make a judgment, and label that 
judgement. Hence, to use a numerical rating scale, children need to have acquired the 
capacity to assign a number to an experience and have the ability to summarize their 
experiences across various episodes. For example, if you ask a child “In the past 7 days, how 
would you rate your pain on average?”, it needs to be a developmentally informed 
assessment. For guidance, self-report measures of pain such as numerical rating scales can 
be used from the age of 6 years onwards.238 There may be difficulties in applying this approach 
to all children due to the cognitive demands of such explicit judgement. It can also be difficult 
to appreciate the influence of other individual, interpersonal, and contextual factors that impact 
the child’s communication or expression of pain. In Box 6 we have captured how pain intensity 
assessment changes with child developmental level. 
 
Box 6: Developmentally appropriate pain intensity assessment methods for children six 
years and older 
 
Using proxies of pain 
In the absence of, or in addition to, self-report, report of the child’s pain by others may be used. 
Researchers or clinical professionals may ask parents or others to make judgments about the 
pain or related experiences of the child when the child is not able to, or to complement the 
child’s report.239 Parents can provide valuable information about their child’s pain experience. 
Nevertheless, one should be cautious about relying solely on other-reports of the child’s pain 




between child and parent do not necessarily reflect inaccuracies in judgment, but rather 
different perspectives on pain or the health problem.242 As such, discrepancies between child 
and parent should not be considered as error obscuring a true score, but as valuable 
information.   
 
For children younger than 6 years or children who are unable to verbally report, behavioural 
scales may provide a valuable alternative to assess pain in clinical settings.243 In infants, these 
may be the first alternative. For example, it may be inferred that a newborn infant expresses 
pain when they are subjected to a procedure that would be painful to adults. Such inference 
is reasonable, given that infants have the basic neurological structures93, 94 and manifest 
behaviours - such as facial grimacing or crying244 - that are analogous to pain responses of 
adults or older children. Currently, the behaviour of children is coded by (trained) observers.245  
Numerous neonatal pain scales have been created, which each calculate pain scores that are 
based primarily on behavioural and physiological observations following clinical procedures.246 
These scales are not substantially different from each other, and most often the pain scales 
prescribe a value to a set of observed behaviours and physiological activity.247 Nevertheless, 
general dissatisfaction with these scales means clinicians and researchers adapt and tweak 
them without the necessary validation steps to make them more appropriate for use in their 
specific settings. This makes it difficult to combine and synthesise evidence about how much 
pain infants are experiencing and whether interventions to prevent or alleviate pain are 
efficacious. 
 
Substantial research efforts are also being targeted towards identifying developmentally 
sensitive surrogate pain measures that can discriminate between responses to noxious and 
innocuous events.248-250  In recent years this has included the use of functional magnetic 
resonance imaging (fMRI), near-infrared spectroscopy (NIRS) and electroencephalography 
(EEG) to quantify changes in brain activity that are evoked by noxious input (Figure 5). These 
brain-derived measures will aid our understanding of the underlying neurological activity 
associated with pain in nonverbal infants. These types of brain-derived measures may also 
prove useful in other paediatric populations who are nonverbal or not able to self-report their 
pain experience.  
 
Figure 5. Assessing pain in infants 
 
We should continue to focus on the identification of robust developmentally-sensitive pain 
indicators so that there are better tools for use in both clinical practice and research. When 
using proxies of pain, it will be important to carefully weigh the costs of false positives or false 
alarms against the accurate detections of pain. Accuracy is a challenge when using proxies 
as the following examples illustrate. Consider that false positive inferences can arise when 
newborn infants display pain-related behaviours in response to non-painful events. For 
example, infant crying has evolved as a non-specific protective mechanism to elicit response 
from caregivers,252 and can be used to signal other experiences, such as tiredness, hunger, 
or discomfort at handling. False negative inferences are also possible, where a newborn infant 
experiences pain, but fails to manifest the usual external signs of pain. For example, extremely 
premature infants can display reduced facial grimacing compared with term-born infants253, 254 
and infants at high risk of neurological impairment can exhibit decreased facial grimacing 
following clinical procedures compared to those who have a low risk of neurological 
complications.255 Notwithstanding these shortcomings, for many patients, such as those who 
are non-verbal, other-reported measures of their pain is the only option. Our confidence in 
their use will increase when there is a strong evidence base documenting the sensitivity and 
specificity of behavioural markers and alternative pain biomarkers.  
 




Frequently we are interested in making future pain visible, or at least in understanding the 
risks that pain might emerge in the future. Being able to predict which children are likely to 
suffer from pain later on, has advantages. It creates windows of opportunities for early 
interventions, and allows the prioritisation of resources (time, personnel, treatment intensity) 
for   those with a high risk for a poor outcome. The growing interest in predicting the transition 
from acute to chronic pain has spurred efforts at identifying risk factors of chronic pain. The 
challenge is to identify the characteristics with predictive value and then to validly measure 
them, as briefly as possible. Research is uncovering neurobiological, social, emotional, and 
behavioural risk factors that are associated with the transition from acute to chronic pain in 
children and adolescents (e.g.,145), and these may form the basis of screening tools. In adults 
several screening tools for predicting chronic pain problems have been developed and 
validated.256, 257 These tools are brief self-report instruments, most often items cover domains 
such as pain and other somatic symptoms, disability, low mood and anxiety, pain-related 
worrying, and expectancies about future pain or disability. Overall, these screening 
instruments are good to excellent in predicting future adverse impact of pain.257 The field of 
clinical prediction is a rapidly evolving field, and guidelines and standards are available to help 
researchers and clinicians to develop and validate such screening tools.258, 259 As yet, there 
are not many screening tools for use in paediatric settings. A notable exception is the 
Paediatric Pain Screening Tool (PPST)260 which is based on  the 9 item  STarT 
Musculoskeletal Screening Tool in adults.261 The content of the items of the PPST has been 
thoughtfully selected and adapted for use in children presenting with pain problems. The 
instrument can be used to rapidly identify treatment targets (e.g. sleep disruption, pain-related 
fear) and to stratify youth into low, medium and high-risk groups to inform referral to 
appropriate interventions. The initial results are promising, and further studies reveal its 
potential usefulness for specific pain populations.262, 263 
 
Going beyond pain and measuring its wider impact. 
Critically, the field of pain measurement has not focussed solely on pain intensity. Indeed, 
progress has been made on making pain visible through the development of measurement 
tools to assess both pain characteristics (e.g., location, frequency, duration) and its impact on 
multiple domains of life. There are many validated tools available to assess pain, physical, 
emotional and social role functioning, and health outcomes in children and adolescents. 
Systematic reviews of measures of pain impact,264 pain-related anxiety,265 sleep 
disturbances,266 observational/behavioural measures of pain,243 and self-report measures of 
pain for very young children,267 and for specific patient populations, such as abdominal pain268 
are available. Despite the efforts of many to go beyond pain and to measure the impact of 
pain on daily life, patient experience is often unexamined. Even in resource challenged 
environments or where routine assessment is frustrated by structural or attitudinal barriers 
there are simple questions one can ask of every child. In Box 7 we suggest a short series of 
questions that can make pain and its impact immediately visible.  
 
Box 7: Routine assessment questions to help make child pain and its impact visible 
 
Core Outcome Sets 
Several notable efforts have been made to develop core outcome sets in paediatric pain. In 
2006, a paediatric working group of the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (Ped-IMMPACT) gathered 26 professionals from academia, 
governmental agencies, and the pharmaceutical industry to participate in a 2-stage Delphi poll 
and a subsequent consensus meeting to identify core outcome domains and measures that 
may be considered in clinical trials of treatments for acute and chronic pain in children and 
adolescents.269 According to the Ped-IMMPACT recommendations, acute pain trials should 
include outcome domains of pain intensity, global judgement of satisfaction with treatment, 
symptoms and adverse events, physical recovery, emotional response, and economic factors. 




physical functioning, emotional functioning, role functioning, symptoms and adverse events, 
global judgement of satisfaction with treatment, sleep, and economic factors.  
 
These recommendations are highly cited as a guide for choosing outcome domains in clinical 
trials and clinical registries. The actual uptake of the recommendations however remains 
suboptimal. Of 337 randomized controlled trials of postoperative pain management, only 2 
outcome domains of the PedIMMPACT recommendations were commonly included; pain 
intensity (93% of trials) and symptoms and adverse events (83% of trials).270 Fewer than 30% 
of these postoperative pain trials included outcomes in any of the other four PedIMMPACT 
domains. In a similar effort, Connelly et al. (2019) recently published a systematic review of 
reporting practices in 107 randomized controlled trials of paediatric chronic pain 
interventions.271 Nearly all trials included pain intensity as an outcome domain but fewer than 
35% of trials included outcomes in the other PedIMMPACT domains. Trials of behavioural 
interventions were more likely to include outcome domains of quality of life, emotional 
functioning, and physical functioning than trials of pharmacologic treatments. Sleep and 
economic factors are rarely assessed across any intervention for paediatric chronic pain 272. 
Overall, these findings indicate that trials of interventions for acute and chronic paediatric pain 
have insufficiently used the PedIMMPACT recommended core outcome sets.  
 
Uptake of the PedIMMPACT core outcome set will increase when the following concerns are 
addressed. First, essential is the systematic involvement of children and parents as 
stakeholders in the entire process. Second, further specificity is needed in recommendations 
or criteria for selecting instruments. For example, multiple outcome instruments are 
recommended rather than one instrument for each domain. Third, there are gaps in available 
measures of several outcome domains (e.g., adverse events, global judgment of satisfaction 
with treatment, and economic factors) hindering their inclusion in trials. Understandably, there 
are challenges in standardizing recommendations because of the large number of pain 
conditions, disciplines, and treatment modalities involved in children’s pain management. 
 
Another well-established core outcome set is the Juvenile idiopathic arthritis (JIA) core 
outcome set, developed in 2014 by Outcome Measures in Rheumatology (OMERACT),273 an 
international group of health professionals, methodologists, and patient research partners 
focused on outcome measures in rheumatology. They originally published a recommendation 
for four core outcomes: life impact, pathophysiologic manifestations, resource use, and 
adverse events. However, because the original set did not include the perspective of children 
and parents, the OMERACT group updated the JIA Core Outcome Set. Morgan and 
colleagues274 reported on this process, which included several strategies to obtain broader 
input including literature review, qualitative surveys, and online discussion boards with 
children with JIA and parents. A Delphi process was used to edit the domain list and achieve 
consensus on domains. Notably, this process led to the inclusion of new domains, and the JIA 
Core Outcome Set now consists of 5 domains: pain, joint inflammatory signs, activity 
limitation/physical function, patients’ perception of disease activity (overall well-being) and 
adverse events.274 Using the rigorous criteria of the ‘COnsensus-based Standards for the 
selection of health Measurement Instruments’ (COSMIN) initiative,275 this group is identifying 
and evaluating the best outcome measures for these domains. 
 
Innovations in pain assessment 
Several innovations in assessment are ongoing, and more are to be expected. A first area of 
innovation is the standardization of patient-reported outcomes through the Patient Reported 
Outcomes Measurement Information System (PROMIS)276 developed by the US National 
Institutes of Health. Over the past decade, considerable work was invested in the development 
of these measures, including use of Item Response Theory and Computer Adaptive Testing, 
and they are now freely available for both clinical and research use. Paediatric PROMIS 
measures include assessments in the domains of mental health, physical health, and social 




by various initiatives. Because PROMIS measures are available in adults, an important 
advantage is consistency in measurement at the upper end of the adolescent/young adult age 
range and in assessing parents/caregivers of youth. Work is underway to validate the PROMIS 
measures in children and adolescents with a variety of painful conditions.277, 278 For example, 
Kashikar-Zuck and colleagues 278 validated PROMIS measures demonstrating treatment 
responsiveness in youth with chronic musculoskeletal pain conditions. Widespread use of 
validated PROMIS measures have been integrated into registries that track patient-reported 
information as part of standard clinical practice  in paediatric chronic pain, such as the 
Pediatric-Collaborative Health Outcomes Information Registry (Peds-CHOIR).279   
 
PROMIS measures include domains that cut across different diseases and settings (e.g., 
physical function, depressive symptoms). There are now > 20 item banks of physical, mental 
and social health for children ages 1-17 years. This includes short forms (4-10 items), 
computer adaptive tests (CATs), and profiles normed to the US general population and 
validated in clinical subgroups. Dutch, English, German, Spanish, and other language 
versions are available. Expanded to clinical practice, quality measurement, population health, 
and international adoption. The measures are publicly-available on www.healthmeasures.net  
 
A further development is the frequent capture of information in the contexts that matter for 
children or their parents. Typically, self-report instruments require children or parents to report 
on their experience over/across a particular time period (e.g., a week or a month). Such recalls 
are affected by memory biases or heuristics, such as the peak (or saliency) heuristic.280 Recent 
technological advances make the real-time capture of information within reach of research 
and practice. Children may be prompted by smartphone notifications to report on their 
experience during randomly selected times during the day (time sampling), or to report on their 
experience when particular events occur (event sampling). Also possible is the passive 
capture of information (e.g., geolocation, physical activity, physiological measurement, bodily 
position, etc). These innovations allow a real-time recording of experience of the dynamics of 
pain and its impact across time and daily contexts. This will provide invaluable information for 
the initial phase of diagnosis, and for the evaluation of interventions using designs that capture 
within-day changes. Ultimately, we could evolve such work into the delivery of just in time 
adaptive interventions, where health behaviour interventions are adapted to an individual’s 
changing internal and contextual state as has been done in other paediatric populations (e.g., 
diabetes 281). 
 
The update of technological innovations is ongoing. There is an increasing use of electronic 
daily diaries in paediatric chronic pain trials, in particular for the real-time measurements of 
pain, physical functioning, sleep, and emotional functioning (e.g., depression, anxiety).282, 283  
Technological advances are abundant in many areas and already profoundly affect research 
and clinical practice. Computerised automated systems for the recognition of pain expression 
and behaviour are being developed, which may lower the burden in observers who code pain 
expression or behaviours.245, 284 3-D motion capture and analysis allow us to evaluate gait 
mechanics, balance, and other functional movements.285 All in all, these technological 
advances occur at an incredibly fast pace, and initial results are promising. Notwithstanding 
the pace of development, research documenting the reliability and validity of these innovations 
is lagging behind. This research is essential because the same criteria for the reliability and 
validity of self-report instruments apply to these technological innovations as they do to 
standard measurement practice. 
 
Clinical relevance and use 
The real test of measurement technology is not its popularity, or how researchers use the tools 
in studies, but whether the routine measurements in paediatric pain produce useful outcomes 
for patients, families and their clinicians. In order to make pain visible, we need to better 
understand whether outcome measures show that pain treatments are effective and safe. This 




understand clinically meaningful change, and research gathering child and family input to learn 
what information they use to determine whether a treatment is working (e.g., attaining certain 
goals, having fewer high pain days).  Novel ways of characterising pain and treatment effects 
are on the horizon. Intensive longitudinal data analyses of the daily pain experience will allow 
researchers and clinicians to identify alterations in the child’s typical pain experience, through 
new analytics, such as dynamic structural equation modelling 286. In fact, regulatory agencies 
are now using longitudinal daily experience data in clinical trials to better understand how an 
intervention makes a difference in daily life for patients.  
 
Standardization of outcome domains and measurement tools for clinical trials of treatments 
for paediatric pain would enhance the quality of the evidence for treatments of pain in 
childhood, strengthen and simplify systematic reviews of paediatric pain interventions, and 
help clinicians make evidence-based treatment decisions for this patient population. In Box 8 
we summarise the main priorities for further investigation and changes in research and clinical 
practice that should be employed to make every child’s pain more visible. 
 
Box 8: Research and clinical priorities to make pain visible 
 
Research and clinical priorities to make pain visible 
We are dragging paediatric pain out of the shadows. We are, however, realistic and know that 
this exposure is confronting for many people. Witnessing others’ distress can be discomforting. 
However, the self-report of internal states is not new. People want to communicate and share 
their experience.287 Accurately capturing private experience and improving its communication 
has been the subject of over 100 years of measurement science.288 In mental health studies 
knowing the structure of the aberrant experience is crucial to the diagnosis of pathology. In 
neurology the description of internal state, cognitive testing, and response to interview can be 
as important in tailoring treatment as brain imaging. In physical medicine there is now a 
recognition that patient-reported outcomes are the missing piece of patient experience that 
can guide more effective intervention, with the growth of interest in patient-related outcome 
measures and core outcome sets.269, 277 And going even further, there is movement toward 
values based healthcare, in which shared decision making by patient, family, and health care 
professionals becomes the norm.289 All rely on the communication of private personal 
experience. 
 
First, pain characteristics should be assessed in every child. It is important to be comfortable 
with assessing internal processes by self-report where possible. Of course, self-report is 
influenced by factors such as social demand (the obedient desire to please), but this should 
not discredit attempts to capture private experience or provide reason to leave pain 
unassessed.  Child pain assessment is an inferential process; we draw from multiple sources 
of evidence. For neonatal pain, researchers and clinicians can capture observer judgements 
of a range of pain relevant observable behaviours, from facial expression and bodily 
expression, and non-verbal utterances including crying. Healthcare professionals need to 
guard against over and under-interpretation, and context can be crucial. For older verbal 
children who are able to form concrete operations and manage metaphor and temporal 
abstraction, one can use measures that assign numbers to experience, or require a judgement 
about time. As introspection develops one can learn to compartmentalise experience. 
Researchers and clinicians rarely go beyond intensity in our measurement practice. But Carl 
von Baeyer, an international expert in pain measurement, reminded us that to describe pain 
by its intensity is like describing music by its volume only.290 Going beyond intensity, at least 
to quality, duration, affect, and interference, and even to its meaning, is possible and desirable. 
 
Second, the impact of pain is not just the experience itself. Pain negatively impacts a child’s 
physical, emotional, and social functioning and healthcare professionals must understand the 
impact of pain on daily life. There are multiple measures to assess domains within these areas 




are conceptually similar areas, a systematic review found seven separate measures.265 In 
chronic pain the measurement of multiple domains of experience should be routine. In 
randomised controlled trials of novel interventions in chronic pain it would now be considered 
poor science to ignore multiple domains of child experience. A consequence of this 
measurement translation of concepts and assessments is that we do not assess concepts that 
are most important to children and their caregivers. For example, friendships, impact on 
career, financial impact, and impact of pain on marital relationships are rarely assessed or 
discussed. Siblings are also ignored. Whilst we need to stop measurement development in 
some areas, it is time that patient-important outcomes are explored, invested in, and 
developed. 
 
Third, most measures where created in a top-down manner, a worrying trend observable 
across the field. Assessments first created and tested in adults, are then ‘simplified’ for 
children, assuming that children have the same worries and fears as adults. Very few 
measures are created ‘bottom-up’. Consolidation of measures out there and careful thinking 
about their developmental validity is important before integrating into a research study or 
practice.  
 
Fourth, as we have highlighted throughout this commission, people are complex. There is a 
need for person-centred approach to assessment of pain in infants, children, and adolescents. 
This will help when allocating patients to optimal treatments to reduce symptoms. In particular, 
children with chronic pain often present with comorbidities, and therefore assessing multiple 
domains of functioning are important to inform which treatments to provide.  
 
Fifth, the next frontier in the measurement of child pain is partly technological and partly 
intellectual. Computing technology has radically altered all biomedical science. Whatever the 
domain of experience we can now capture large amounts of data. Consider that the near 
ubiquitous adoption of mobile telephony means that the passive capture of geolocation and 
movement sensing data is now easy. ‘Near-time’ assessment of behaviour linked to a specific 
antecedent target is also possible, so we can assess the context of specific behaviours and 
experiences. So called ‘big’ data creates the possibility for machine learning to identify 
population patterns of data, which has been used to follow patterns of disease and its 
alteration, and could be used in pain to assess environmental influences of pain. 
 
Goal 4: Make pain better.  
Every child should have access to evidence-based pain assessment and subsequent 
treatment using the currently most effective methods and means. A growing number of high 
quality systematic reviews, meta-analyses, and clinical practice guidelines demonstrate 
efficacy for at least some psychological, pharmacological, physical, and/or integrative 
treatment modalities to reduce pain and improve function.32, 291-295 These treatment strategies 




We will not provide an exhaustive review of all possible treatments here. Physical, 
psychological and pharmacological treatment have their own relevance to paediatric pain 
management, as different approaches may work for different children of different ages, at 
different times, and in different circumstances. In chronic and episodic pain, psychological 
treatments have the most robust evidence base of all treatment modalities, having been the 
most studied, in particular with older children 272. Effective psychological treatments are 
predominantly based on cognitive and/or behavioural therapies and target cognitions, 
emotions, and behaviours, most notably cognitive-behavioural therapy (CBT).296-299 The 
therapeutic aim includes prevention of episodic pain such as headache or recurrent abdominal 
pain, the mitigation of severe or unavoidable pain, or the management of the aversive 




robust for procedural pain, including distraction, hypnosis, combined CBT, and breathing 
interventions297. There are many primary studies and evidence syntheses of psychological 
therapies delivered to children and adolescents with pain, including hypnosis,297 problem-
solving therapy,300 acceptance commitment therapy,301 mindfulness,302 and memory 
reframing303 amongst others. Data on possible harms from these approaches is rarely 
collected and so unavailable.304 
 
Physical interventions are commonly used to address both acute and chronic pain but the 
literature supporting them is not as robust as their use would suggest. Investigation of physical 
interventions for paediatric pain has largely focused on those available for preterm and term 
infants and young children during medical procedures. Evidence supported interventions 
include non-nutritive sucking (such as using a pacifier), swaddling/facilitated tucking, skin-to-
skin contact, rocking, and holding (such as comfort positioning).305-307 Other contextually 
relevant strategies to effectively reduce acute pain and distress direct how procedures are 
conducted (such as simultaneous injections) or alterations to the environment (such as low 
noise and lighting, and soothing smells).305, 306 Evidence for physical interventions for 
paediatric chronic pain is less common 272, although neuromuscular exercise training 308  and 
aerobic exercise appear promising.309 The limited adult literature on other physiotherapeutic 
techniques such as transcutaneous electrical nerve stimulation has been extrapolated to 
children and this modality is in common usage in children and young adults 310, 311. 
 
Reviews of integrative therapies highlight the interest in acupuncture, creative arts, herbal 
therapy, homeopathy, and massage therapy for different pain conditions,312, 313 however, the 
evidence is scarce. Evidence suggests that improving patient or family understanding of pain 
and its mechanisms through the provision of pain education may also provide some 
therapeutic benefit.314 Furthermore, given the complex biopsychosocial nature of all pain 
experience, efforts to consolidate scientific evidence to inform multi-modal paediatric pain care 
are noted in clinical practice guidelines to address acute/procedural,35 perioperative,293 and 
chronic315 pain management from infancy to late adolescence.316 
 
Although there is a growing research interest in physical, psychological and surgical 
interventions, by far the most commonly used treatments are pharmacological.  
Pharmacotherapy for pain, both acute and chronic, includes paracetamol,317 topical 
anaesthetics,318 sweet-tasting solutions,319 non-steroidal anti-inflammatory drugs,320, 321 
antiepileptic drugs,322, 323 antidepressants324, and opioids.325-327 However, despite the common 
use of pharmacotherapy, its ubiquity, and clinical utility, there is very little research on existing 
or new agents, particularly in the area of chronic pain management. Although not 
pharmacological, there is also evidence for the efficacy of breastfeeding for babies 
experiencing acute pain.328 In a recent overview of systematic reviews only six randomised 
controlled trials of analgesic pharmacological interventions for paediatric chronic non-cancer 
pain were identified and no trials for chronic cancer-related pain,329 meaning that the evidence 
base for the most common treatments used in children with chronic pain is based on few trials 
with few patients. Similarly, the use of interventional procedures (such as nerve blocks and 
neurostimulation) for paediatric chronic pain is supported primarily by case reports with few 
randomised controlled trials (RCTs).330 Although there are more RCTs for paediatric 
perioperative care, evidence from adults is often extrapolated to paediatric populations.329 This 
mirrors a lack of clinical drug trials across other areas of paediatric health.293 A more 
substantive indirect evidence base supports pharmacological treatments and regional nerve 
blocks for paediatric acute, postoperative, and procedural pain 331.  
 
An absence of evidence is not the same as evidence of an absence of effect, and there is a 
growing need for new treatments.332, 333 This should lead us to ask why there is no concerted 
effort to capture data on the efficacy and safety of existing medicines, or to develop new 





Practices of analgesic decision making 
Analgesic provision for both acute and chronic pain is often guided by local culture or attitudes. 
A good example of this is in analgesic provision for infants and children post-operatively. 
Analgesic medications are not licensed for pain management in newborn infants, so the choice 
of treatment is left to clinical judgement. Therefore, the choices of drug, dose and route of 
administration are selected based on expert consensus and individual experience, which may 
not be supported by strong evidence. Consequently, so called ‘off-label’ analgesics are 
commonly administered to infants, in unsuitable formulations, with limited knowledge of the 
pharmacokinetic properties, drug efficacy or safety. Furthermore, as developmentally very 
distinct, children are frequently grouped together across a broad age range, and in the 
absence of adequate data due to the paucity of studies, regulatory decisions designed to 
protect some children can have unintended effects on access to analgesia for a greater 
number of children who are at low risk. An example of this has been the regulatory response 
to cases of respiratory depression following codeine 334-337, that have effectively led to 
analgesic compounds such as codeine and tramadol 334, 338 becoming unavailable to 
increasingly large numbers of children after surgery.   There is an urgent need for analgesic 
drugs to be studied and licensed in children, especially infants, and stronger links between 
academia, industry, regulatory bodies, parents and their children is essential if we are to 
improve the treatment of pain. A clear pathway from identifying optimal endpoints to measuring 
drug efficacy and safety through to licensing should be forged. International collaborations 
need to lead the way and be supported in their efforts to provide safe and effective treatments 
for the neonatal population. 
 
Of course, many treatments do not lend themselves easily to randomised controlled trials and 
the right course of action is not immediately clear. For example, there are considerable 
uncertainties in how to manage pain in newborn or preterm infants, where it can at times be 
unclear as to whether or not the infant is experiencing pain, this is also true for many children 
with communication impairments. This leads to ethical questions related to how best to treat 
pain, as the reduction or avoidance of pain is not a goal without costs, where favourable 
analgesic effects can seem inseparable from unfavourable adverse effects.29 As an example, 
considerable uncertainty exists regarding whether preterm infants should receive pre-
medication when they are receiving surfactant by so-called “minimally invasive” techniques.339, 
340 These techniques involve laryngoscopy and passing a fine bore catheter into the larynx to 
administer surfactant to the spontaneously breathing infant. In part, the proposed benefit of 
this technique is attributed to the belief that the infant’s spontaneous breathing distributes 
surfactant more effectively than would be the case if it was applied using positive pressure in 
a non-breathing infant. However, we do not know how distressing laryngoscopy without 
sedation or analgesia is for extremely preterm infants, although it seems safe to assume that 
it is unpleasant. The provision of sedation or analgesia presumably reduces the infant’s 
discomfort (though this is difficult to evaluate); however, it also appears that even low dose 
sedation is associated with increases in episodes of blood oxygen desaturation and the need 
for manual ventilation during the procedure.341 
 
This question is not only a clinical question, but an ethical one: how should these risks be 
balanced? Is it worse for the infant to have a more unpleasant procedure, or to have more 
episodes of oxygen desaturation and increased likelihood for the need for ventilation and 
consequent increased morbidity? This example highlights the way that decisions about pain 
management are often posited where it is necessary to weigh different values. Greater clarity 
about the adverse effects of early life pain compared to increased physiological instability may 
be possible as more evidence is acquired. However, there will still be a need to decide which, 
and whose, values to prioritise. In light of these balanced ethical considerations, a 
recommendation based on the precautionary principle is made. We should, where possible, 
make all efforts to limit pain exposure by avoiding pain-causing procedures. Where these 
procedures are unavoidable, interventions to alleviate pain should be used that have been 




an unknown balance between the potential benefits and harms associated with these 
decisions, and this is likely to vary. Parents should be involved in decisions relating to pain 
management in their infants and children so that their views and values are considered. 
Medical care providers need to be aware of the drugs they are administering, recognise their 
potential complications to inform parents, and also possess the skills and strategies to resolve 
these complications as they arise.  It is important to see more involvement of clinical ethicists, 
or perhaps the public recognition of the involvement of clinical ethicists in the questions 
surrounding paediatric pain management, especially in infants and children who cannot 
verbally communicate. 
 
Even in working with older children who can communicate complex needs, there is absence 
of primary study, and a lack of pull through from theory to pre-clinical study to clinical 
intervention research. For example, one of the most examined areas of paediatric pain 
management is child-focussed psychological treatments. However, there are important areas 
that are missing. First, there are few studies that include parents, siblings, and peers, although 
they are starting to emerge.300, 342, 343 Second, there is a distinct missing focus on prevention 
of pain, its exacerbation, or its maintenance in both post-surgical and chronic primary pain 
conditions. In post-surgical pain up to 20% of children and adolescents go on to report long-
term pain344 and in chronic primary pain, treatments have not been developed, and risk factors 
are just starting to be identified.143, 145 
 
Promoting evidence based paediatric pain management 
In adopting a meta-scientific approach we could appear unduly and unhelpfully critical. In 
dwelling on the practically, ethically, and clinically complex we are not promoting a nihilistic 
abandonment of scientific endeavour. Complexity is the starting point, not the destination. To 
make pain better, there needs to be more creative and far-reaching methods to evaluate new 
and emerging health technologies. As a community, we are at a critical turning point in the 
production of evidence.  If we do the same as we have done before we will get the same 
results. Further, the common methods and study designs might not be up to the advances 
needed to quickly advance in this field. For example, the gold standard trial design is 
commonly presented as the randomised controlled trial. However, in many cases the 
randomised controlled trial is unethical, impractical or both 345, such as in testing the 
effectiveness of pharmacological interventions in a palliative or end of life setting when 
randomisation without a viable rescue medication would be unethical and difficult to justify. 
The blinded randomized controlled trial is a gold standard in clinical evidence production 
because it evolved as a method to control for known biases in evidence production (see 
Cochrane Risk of Bias tool),346 but this methodology should not be thoughtlessly evaluated 
when reviewing evidence.  
  
Increasingly common are practical designs such as stepped-wedged design in which centres 
or individuals can act as their own control for varying amounts of time before beginning 
treatment.347 Similarly, the use of single case series, in which an individual can act as their 
own control are being re-introduced.348, 349 For a second example, consider that most of the 
studies included in a recent review of interdisciplinary chronic pain care were single-group, 
pre-post design.315 This review found significant differences from after treatment on most 
outcomes, including pain intensity, physical and emotional functioning, and school attendance. 
Needed in this case is a focus on methods for describing complex interventions, including the 
content of the intervention, using criteria such as available templates for intervention 
description and replication (TiDieR),350 and open availability of manuals with full treatment 
descriptions to allow for an analysis of active components. Hybrid effectiveness-intervention 
designs also provide a methodology to evaluate efficacy of interventions as well as 
implementation to determine how the intervention can be integrated within clinical settings.351 
 
One way to improve the quality and quantity of evidence for how to help children in pain is to 




funders. Where appropriate, there should be a move away from the adoption of non-bespoke 
research methods from another field of study, or from another time or population, and go back 
to basics. The reason the randomised controlled trial and its constituent parts is popular is 
because it successfully introduced ways to manage bias. The methods and associated 
statistics were created, however, to support agriculture not medicine,288 only later being 
transferred across to the study of humans. In asking how to design a study to evaluate the 
efficacy and safety of any intervention, either clinically for the individual you are trying to help, 
or as trial on a sample of population with need, one needs to understand how to manage bias.  
 
One must always be critical when reviewing evidence in any field, and paediatric pain is no 
exception. Most funders and many journals require trials to register aims, hypotheses, and 
assessments a-priori on online registries (e.g., clinicaltrials.gov). If primary or secondary 
outcomes measures differ from registration to publication, or if important outcome measures 
are missing at publication that were registered, this may lead to suspicion unless addressed 
adequately.352 There are other key considerations when interpreting evidence for the 
treatment of paediatric pain, including managing and interpreting risk of biases, size, and 
quality of evidence. Depending on trial design, trialists should reduce bias and fully report 
methods wherever possible. Biases that are important in randomised controlled trials are 
outlined in the Cochrane Risk of Bias tool.346 Full and transparent reporting will increase 
confidence around the estimate of effect and improve our evidence-base, rather than adding 
more uncertainty.353 In regard to size, there is a large body of literature that strongly argues 
that size matters when analysing and interpreting evidence from pain trials.354 Trials with fewer 
than 50 participants overestimate the treatment effect around 50% of the time.355 This can also 
be seen in a recent review of psychological interventions for children with chronic pain298 which 
found small trials produced a large beneficial treatment effect for reducing pain, compared to 
larger trials which found no beneficial effect. Therefore, larger trials will also help increase 
certainty, as smaller trials typically over-estimate effects of interventions. 
 
Finally, it is important to interpret the quality of evidence with the effect of treatment. The 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) is most 
commonly used in healthcare evidence.356, 357 Using this system, outcomes are rated from very 
low (we have very little confidence in the effect estimate; the true effect is likely to be 
substantially different from the estimate of effect) to high (we are very confident that the true 
effect lies close to that of the estimate of effect). Therefore, even when interventions show a 
very large beneficial effect, or a null effect, the quality of evidence is important to interpret what 
will guide clinicians, researchers, and policy makers on how reliable that evidence is, and how 
likely it would be to change if new trials were conducted.  
 
Improving available treatments  
Another way to make pain better is by working with what is known already. A good example 
is in the application of the pharmacokinetic and pharmacodynamic properties of analgesics in 
the developing child. Medical practitioners caring for children in pain want to know how 
effective a drug is likely to be and to know the optimal dose, timing and route of administration. 
While they may be aware that the dose should be reduced in the very young, there are often 
uncertainties about how much the dose is reduced or what reduction is required for a loading 
dose as opposed to a maintenance dose. Dose reduction could be attributable to either 
pharmacokinetic (commonly defined by clearance (CL) and volume of distribution (V)) 
combined with a pharmacodynamic effect (often defined by maximum effect (efficacy or EMAX) 
and the concentration at which half that maximum effect is achieved (C50)). These parameters 
are associated with variability. Quantifying and sourcing this variability and how it relates to 
dose in the individual child helps clinicians to personalize drug use. This method avoids the 
concept that one dose fits all, regardless of age, maturation, or disease process. It also 
sidesteps the approach where pain relief only has merit if it decreases by a predetermined 
value (e.g., 50%). Determining the ‘right’ dose is achieved by the use of target concentration 





Figure 6. Determining correct dose in a target concentration analgesic strategy 
 
Population pharmacokinetic-pharmacodynamic (PKPD) modelling can be used to determine 
key parameters such as CL, V, EMAX and C50. This modelling is a Bayesian statistical method 
in which mathematical equations are used to describe the typical (or population) time-
concentration and concentration-response relationships observed after drug administration. 
Compartment models are usually used to describe drug disposition. This approach has been 
extended by integration of physiological parameters into the equations. The Hill equation, used 
originally to describe oxygen dissociation358 has proven popular and versatile to describe drug 
response, although other descriptors are equally valid. This methodology involves 
determination of a desired target effect and that in turn requires a robust pain measure or 
measures. Description of a concentration-pain response relationship allows assessment of 
pain relief on a concentration continuum. Simple relationships for ibuprofen359 and 
diclofenac360 determined for acute pain after tonsillectomy using a visual analogue scale (0-
10) are shown in Figure 7. 
 
Figure 7: A concentration-response relationship for ibuprofen and diclofenac, determined for 
acute pain after tonsillectomy 
 
 
Population PKPD modelling uses mixed effects to study variability in drug responses in 
individuals who represent those in whom the drug will be used. If the variability between 
patients is modelled, then it is possible to predict the magnitude of the difference between 
predictions and the observations in the next subject.362 Variability is associated with all 
parameters used in PK and PD equations. Covariate information (e.g. weight, age, pathology, 
drug interactions, pharmacogenomics) can be used to help predict the typical dose in a 
specific patient, reducing population parameter variability. This type of modelling aims to 
personalise medicine. 
 
Pharmacogenomics is one area that can provide information to individualise treatment. The 
drug irinotecan, used to treat cancer, has an active metabolite that is metabolised by a 
glucuronide (UGT1A1); a pathway similar to that involved in morphine clearance (UGT2B7).  
A variant allele UGT1A1*28 has been identified that is associated with severe neutropenia 
and diarrhoea. Genetic testing in patients to identify this allele (present in 10% Caucasians) 
has been shown to be beneficial in adults.363 Single polymorphisms that control the hepatic 
enzyme CYP2D6 influence metabolism of drugs such as codeine, tramadol and amitriptyline, 
drugs commonly used in pain management. Consequently, this enzyme contributes to 
observed effects and adverse effects. It is possible to perform bedside testing to assess 
genotype and that information can be used to review dose. Although genotype dose not 
always equate with phenotype,364 such information can be used as a guide for initial dosing. 
 
We accept that genetic influences are complex and may prove difficult to unravel. It remains 
uncertain how much an understanding of pharmacogenomics will play in dose 
individualisation. If a single genetic variant was responsible for major PK or PD differences, 
then dose individualisation would be easier. However, there appears a multiplicity of genetic 
influences on both morphine PK and PD and the impact from interaction of these variants are 
not fully understood. Pain response is further complicated by numerous other factors (e.g. 
psychosocial, race, environment, underlying pathology, age).365 We need to understand these 
complexities before they can be used to individualise therapy.   
 
We present this in full as an example of an approach to optimise drug management that is 
rarely used for children with chronic pain but could be an effective way to radically improve 




education around the pharmacokinetic and pharmacodynamic properties of analgesics in 
children.  
 
This approach to personalisation could have merit across many of the existing treatments. 
Whilst assessing the pharmacokinetic and pharmacodynamic properties of drugs can help to 
optimise pharmacological interventions, other strategies can be used, for example, with 
psychological treatments. Within research of children with chronic pain, researchers are 
starting to stratify children and provide more targeted treatment modalities. Children with 
chronic pain often have comorbidities, such as anxiety, depression, post-traumatic stress, or 
higher levels of insomnia. Therefore, trialists have started trying to combine treatment 
modalities and test efficacy of delivering pain and insomnia CBT together282 or deliver anxiety 
and pain CBT366 with promising effects. In addition, from the RCTs already conducted, 
researchers are also investigating who reports the greatest gains in treatment. For example, 
studies have found that parent factors at the beginning of treatment could predict children who 
make the most gains after treatment.367, 368 For example, parents with higher distress pre-
treatment predicted less improvement in child disability 12 months following treatment, 
compared to parents who reported lower distress.368 This indicates that for those caregivers 
with high distress, it may be important to target their own distress early in treatment, to effect 
change on child disability. This is critical information for refining psychological therapies and 
providing more individualised treatment. 
 
Improving access and scale 
One further way to make pain better is by working to increase access to the available 
treatments, and by extension increase their scale of production. We have already highlighted 
the important contribution of knowledge translation and provided examples in Table 1. 
Researchers have risen to the challenge of improving access to evidence supported 
treatments in the use of computing technology to deliver psychological, educational or nursing 
led treatments that have behaviour as a core target of the intervention. Just as technology has 
started to be used for assessment, investigators began exploring the use of computing 
technology for treatment. There is a relatively long history of attempts at using technology to 
increase access (e.g., the telephone)369 and at the automation of instruction or therapeutic 
direction.370 Often these attempts have expanded as computing technology became 
ubiquitous. For example, as we write the number of mobile data connections runs at more 
than the population in most countries, meaning that per population people have more than 
one device connected (https://ourworldindata.org/grapher/mobile-cellular-subscriptions-per-
100-people). The dominance of the phone and the growth of computing in ‘smart’ phones has 
led investigators to both transfer face-to-face technologies onto these platforms, and to 
attempt innovation in new treatments that can only be delivered remotely.371-373 One 
systematic review identified ten randomised controlled trials testing the efficacy of remotely-
delivered treatments for children with chronic pain, and found small effects for reducing pain 
intensity and disability after treatment.372 However, the long-term effects of these are currently 
unknown. 
 
Despite the large number of apps delivering pain education and treatment, very few that have 
been developed are supported by evidence or based on a theoretical framework. There are 
some very good examples of how technology has been successfully used to improve access 
to treatments (e.g., 374) Less successful have been attempts at increasing the scale of access 
to treatments.  Those that have been developed by scientists and tested for efficacy, often in 
University settings, are typically difficult to commercialise.375 For example, fewer than 30% of 
researcher-led applications for paediatric pain assessment and management became 
available to users, accounting for on average $300,000 of grant funds for each application.375 
Scalability and sustainability remains a challenge and may actually involve reassessment of 
how to develop treatments, and our relationships with commercial providers, health care 






One country that has made online, evidence-based psychological therapies for mental and 
physical health freely available is Australia. The eCentre Clinic (https://ecentreclinic.org) at 
Macquarie University has developed over 15 interventions for mental and physical health 
conditions, including panic attacks, depression, social anxiety, post-traumatic stress, chronic 
pain (in adults), diabetes, epilepsy, amongst others, in both children and adults. Once an 
intervention has been determined to be efficacious, it is made freely available to Australians. 
Often, participants accessing the interventions agree to be included into the research studies. 
The eCentre Clinic have conducted over 40 trials of over 4000 Australians testing these 
interventions to establish efficacy and safety.  
 
Embracing complexity 
Finally, in delivering the ambition of how to improve the effectiveness, safety, quality, access 
and scalability of the available treatments, there should be a focus on the context in which 
these treatments are to be delivered. Much of the evidence is based on single studies or the 
amalgamation of those studies in research synthesis. On translation from the research to the 
clinical setting there are three specific challenges: co-morbidity, ecological validity, and 
specificity.  
 
Very few patients present with a single condition.377 Although medicine has arguably become 
fragmented through specialisation and super-specialisation, and there is a general tendency 
to see a patient through the lens of an individual’s specific or specialist training, the skills and 
experience of the more general practitioner or child health worker are equally important.  Pain 
is often being managed in the context of disease or after immunological challenge, as in 
surgery. In the neonate, as described earlier, fast developing systems often at a critical stage 
of shaping, need to be understood in any analgesic strategy. In children with neurodisability 
pain from multiple sources, for example muscle spasms, and complex co-morbid conditions 
such as sleep-apnoea syndrome are frequent. In the adolescent with chronic pain, comorbid 
mental health problems are common and should be considered in any plan.372, 377 Trials in this 
area often exclude those with more complex diagnoses and aim to improve physical 
functioning. Despite the comorbidities often seen in child and adolescent populations, RCTs 
in this field provide little treatment to manage anxiety and depression, and therefore, there is 
little change in their symptomology after pain treatment.  
 
Our habit of excluding complexity in clinical trials and other research designs by excluding 
patients with multiple needs has led to gaps in our knowledge which are felt most acutely when 
faced with variety in patients presenting for help. Attempts have and are being made across 
paediatric pain to address problems in the ecological validity of trials used to guide practice. 
For example, there are recent studies in populations that are typically excluded from trials 
such as those from low income communities 378 or those with complex co-morbidities366. More 
needs to be done to reach these groups and those failing to present with manageable disease 
due to assessment difficulties, stigma, fear of social exclusion, or a coping strategy of 
minimizing adverse health concerns. 
 
One size does not and should not fit all. Not all treatments work for everyone,379 exemplified 
by a desire to individualise and personalise pharmacotherapy. Sex and gender influences 
treatment outcome,380 as do genetic factors in later development of pain sensitivity or drug 
metabolism.381 Many factors beyond the individual child are also relevant, such as parent 
distress368 and the social context surrounding the child.  A challenge for us will be to use what 
is known about what makes pain better as a foundation on which to build. That will mean 
understanding not only the evidence but the strengths and weaknesses of our habits of 
evidence production.  
 





We have to get smarter with how we make pain better; in trial design, treatments, what we 
deliver and to whom. There are currently serious shortcomings in treatment plans for children 
throughout the developmental age-span which need to be addressed (Box 9).  
 
First, there are some fundamental gaps in the ambition to make pain better for all children and 
we need to innovate solutions to overcome our shortcomings. We have very little evidence for 
or against most pharmacological treatments commonly used in pain with needs being greatest 
for acute pain indications in the youngest children, and chronic and long- term pain for all age 
groups.251, 329 This situation is far from new, and in recognition of the widespread lack of data 
for medications in children the Best Pharmaceuticals for Children Act (2002)382 and the 
Pediatric Research Equity Act (2003),383 in the USA and the Paediatric Rule (2007),384 in 
Europe, were introduced. This legislation was designed to incentivise or require 
pharmaceutical companies to conduct RCTs with children, and include paediatric formulations 
where feasible; unfortunately, these strategies, although welcome, have clearly had limited 
success in the field of pain. The lack of suitable data has driven calls for newer and different 
approaches and modification of trial designs although the perception persists that these kinds 
of studies are difficult and impractical to conduct.385, 386 Nevertheless, we do need to consider 
alternative approaches to providing evidence to guide clinical practice that goes beyond the 
pharmacological RCT. The RCT was introduced to manage specific human influences which 
are known to bias outcomes of studies, masking any true effect of a novel health technology, 
and it manages some of these biases well. However, the RCT is expensive, time consuming, 
often inconclusive, and difficult to translate into clinical practice. They incur opportunity costs 
for alternative ways of exploring efficacy and harm for the individual patient. Nevertheless, 
large, multi-site trials that are free from bias will increase the confidence in the estimate of 
effects and provide clinicians with confidence when treating patients.   
 
Second, there is a pressing need for novel drug discovery, in particular, medications that do 
not stimulate the reward system especially in this era of concern about opioid misuse. We 
encourage variety in clinical studies, especially in studies of efficacy. The analysis of a close 
investigation of pharmacokinetic-pharmacodynamic profiling was one such example. Often, 
healthcare professionals are dealing with older analgesics (e.g., morphine), the properties of 
which are well documented and understood at a population level and in multiple clinical 
samples.  Quantifying and determining the source of variability in response, and how the 
variability relates to dose, route of administration, and scheduling in the individual child can 
help clinicians to personalize their analgesic strategy. One size does not fit all. Optimal drug 
management can be done at an individual level. Often individual hospitals and individual 
physicians treat patients by essentially conducting single case designs when prescribing and 
switching drugs in children in order to manage their pain. However, these procedures are not 
systematically and fully reported in an accessible way. Creating a shared national or 
international database of essential participant characteristics (age, sex, weight, height, 
diagnosis), prescription (drug, dose, route), and outcomes (pain intensity and interference, 
adverse events, functioning) that can be systematically recorded and shared will further our 
understanding of which drugs work for children with different pain conditions. Although there 
is a strong tradition of single case studies in clinical psychology387 their application in paediatric 
pain is rare,349 but examples exist in adult pain research.388 Paradoxically, focussing on the 
individual might allow us to imagine ways to increase access to evidence supported treatments 
and to scale up the production of those treatments. 
 
Third, there is a need to intervene earlier to prevent onset of chronic pain. Identification of risk 
factors and tailoring of treatments could accelerate progress in this field. Early prevention is 
likely to reduce personal and societal effects of developing chronic pain, particularly in 
childhood. Psychological and physical interventions could be particularly useful in this domain, 
providing children and their parents with skills and understanding of pain management. Much 
of the trial evidence to date has focussed on managing chronic or procedural pain, but 




interventions delivered at community level, could dramatically reduce the numbers of children 
transitioning from acute to chronic pain after injury, surgery, or other.   
 
Fourth, there is a need to stop some trials in the field where we have sufficient evidence, or 
further evidence is unlikely to change our confidence in the estimate of effect. One example 
is for psychological interventions for chronic pain, although there are other examples we could 
present such as distraction for children undergoing procedural pain. It is unlikely that more 
RCTs of psychological interventions, however well conducted, will reduce the overall 
uncertainties around effect estimates. The next steps in psychological treatment research 
should be to establish an evidence base for 1) complex participants with comorbidities, aimed 
at reducing distress as well as improving function, including parents, and improving social 
outcomes for participants, and 2) for prevention of long-term pain in children and adolescents. 
Although commonly used in practice, physical interventions for chronic pain would benefit from 
rigorous evaluation to better understand the role of the specific techniques versus general 
conditioning versus the ongoing relationship with the therapist. However, wherever trials are 
being reported, so should adverse event data. These are frequently missing in psychological 
the interventions.298  
 
Finally, a benefit of an idiographic approach to research, in focusing on the single case, on 
the person, is that complexity ceases to be a problem and becomes the solution. We are 
interested in the peculiar, the unusual, as every case is ordinary in relation to itself. Our focus 
is on what works for the person, and complexity is the norm. For some, that complexity will 
likely involve co-morbidity, and polypharmacy, and will include a personal learning history and 
a specific environmental and learning context. Complexity science could be helpful in 
determining novel individualised treatments. If we can use the pain related data (big and small) 
made visible by the pervasive personal sensing and computing, we can start to use it for 
treatment. 
 
Meaningful and lasting change: Action for policy makers and funders 
Child pain matters. But not, it seems, to everyone, not for every child, and not for every pain. 
We have to work harder to make child pain matter to all, be understood and be visible; to make 
it important enough to bring out into the open and to act upon. Only then can pain be made 
better. However, these goals are not sequential, each must be addressed simultaneously to 
improve the well-being of infants, children, adolescents, and the adults they become.  
 
The WHO–UNICEF–Lancet special commission on securing a future for children recently 
argued that children should be put at the centre of action to meet the sustainable development 
goals, that a focus on the health and wellbeing of children is essential to population survival.389 
Here we focussed on pain within developed countries. We welcome a focus on child thriving, 
on the promotion of cognitive, emotional, and motivational resource, and on positioning 
children as central to political action. Children’s ability to drive sustainable change should not 
be underestimated, nor should the degree to which young people care about a positive future 
for all. 
 
Consensus on the importance of child health and wellbeing is an important start. Amongst 
healthcare professionals it is easy to agree that no child should experience pain if that pain 
can and should be prevented, avoided, or successfully treated. In practice, however, there is 
ample evidence that children frequently experience preventable pain, and that in high income 
settings with advanced health care systems, and highly educated and regulated health 
professionals, children, from newborns to emerging adults, experience pain that goes 
unnoticed, unreported, or is not responded to.390 Asserting a voice in pain can lead to social 
rejection, marginalisation, and stigma. Advocating individually for a child in pain can bring 





In this commission we set out four critical goals, that if achieved, will transform paediatric pain; 
making children’s pain matter, understood, visible and better for future generations. As we 
described at the start of this commission, these goals may seem obvious and many people 
may believe that they have confidence in successfully actioning them every day. However, we 
challenge everyone to step back and reconsider how they can further improve their clinical 
and research practice based on these goals. We sought to understand the reasons for the 
discordance between a belief in the importance of a goal, in what is thought correct and morally 
defensible, and the collective inaction in organised attempts to deliver that goal.  Casting the 
problem as a social science, one in addition to a psychological or medical one, can help 
reframe our future investigations. We do not suggest that individuals deliberately hurt or harm 
children by their actions or inaction. It is the individuals working to improve the lives of children 
and family who advocate for children in pain and deliver the solutions needed. 
 
Here we focus on priorities for policy makers and funders that will enable healthcare 
professionals, researchers, patients and families to be able to achieve these goals (Box 16). 
At the beginning of the commission we asked how much of what we do (or fail to do) now for 
children in pain will come to be seen as unwise, unacceptable or unethical in the next 40 
years? It is only by cross-sector collaboration between researchers, clinicians, policy makers, 
and funders that progress can be made quickly and effectively. We need a coordinated 
approach on all fronts, from all disciplines and agencies. 
 
Box 10. Priorities for policy makers and funders 
 
On a national level, longitudinal data are needed to fully understand the impact of pain 
experienced during childhood on later development and achievement. Although there are a 
number of databases which exist, pain often does not play a central role in such databases, 
despite it being a primary symptom of many diseases and illnesses. Children who experience 
pain during childhood are likely to go on to report pain in adulthood, so understanding the 
impact from inception is critical to understanding the later impact. A coordinated approach 
between countries is essential so researchers are able to compare the prevalence and impact 
of pain across cultures.  
 
As evidence for understanding, assessing and treating pain continually evolves, so should the 
education of the healthcare professionals involved in this domain of care. As highlighted in the 
inequity of care, specialist knowledge to treating pain is often centralised. Greater efforts are 
needed to educate those in community settings to be able to treat neonates, children, and 
adolescents with pain. Improving curricula for all healthcare professionals is critically needed 
to include information on pain assessment and management, so that the healthcare 
professionals are better equipped to manage pain and not perceive it as a bi-product of a 
procedure or disease. In addition to this, curriculum revision is needed for medical nursing and 
allied health students treating future children with pain, who receive relatively little information 
about assessing and managing pain across the childhood lifespan, as well as regular re-
training for front-line staff treating neonates, children, and adolescents.  
 
Knowledge mobilisation is another strategy that could be key in reducing inequity in healthcare 
knowledge. There is now an active discussion about the importance of bridging the gaps 
between knowledge and its use, between science and clinical practice, and between patient 
experience and the design of services. We highlighted examples (Table 1). There is a need 
for other countries or international efforts to develop similar knowledge mobilisation networks 
to promote awareness of the problems of pain. There is also a need for countries or 
international efforts to develop knowledge mobilisation networks to promote awareness of the 
problems of pain, particularly in an ever-increasing digitalised world where healthcare 





Inequities in the provision of services need to be addressed. Clinically, there has been a 
growth in provision of dedicated child pain centres (e.g., https://www.iasp-
pain.org/About/Content.aspx?ItemNumber=7916) and in many countries there have been 
successful attempts to audit and benchmark practice against a standard. However, there is 
still a long way to go. Most of these treatment centres are in urbanised areas under specialist 
professionals, yet it would be naïve to think that children only experience pain in these settings. 
There is benefit in gathering such knowledge and specialism in centres, but it can be to the 
detriment of children experiencing pain elsewhere, and to those who cannot always access 
these healthcare centres. When children reach treatment centres, their pain should be 
managed by healthcare professionals who have up-to-date knowledge. This means regular 
training, practice reflection, supervision, and resource. 
 
Multidisciplinary treatments are considered the gold standard of care in this area, but despite 
the prevalence of pain in children, the services available to them often lack behind those of 
adults. There is evidence that pain experienced during childhood is reported in adulthood 392, 
and children do not spontaneously recover from chronic pain once it is reported 393, and 
symptoms deteriorate whilst awaiting interventions or clinic appointments 394. Therefore, 
funding for sustainable multidisciplinary services are critical for managing pain in these 
children and adolescents.  
 
There needs to be a shift to make healthcare individuals and organisation leadership take 
charge of patient care and increase accountability. As we have advocated, all pain should be 
assessed and treated. Where that does not happen, a failure of care is occurring. Where pain 
is unassessed or untreated, intolerance needs to replace tolerance. Children are in pain now, 
across the world and more should be done to manage that pain. This includes making pain 
visible by targeting funding and policy to those who have been ignored or received inequity in 
pain management. As we discussed earlier, we are not talking about equal access to all 
resources, but fair access to unequal resources. Research funding is need to illuminate 
inequity within healthcare and community settings, so this can be rectified.  
 
Diverse leadership at an organisational level is critical to dealing with local child pain 
challenges that present within the institution or region. Patient-partners are important to 
include in these leadership teams, providing a different perspective to other professionals and 
providing a voice of those who are subject to assessments and interventions. Driving the 
awareness of pain across the developmental lifespan and developing solutions at local levels 
is important.  
 
With leadership will come novel innovation including new models of care. For example, we 
have yet to see ‘small data’ innovation 395, where by small data we mean the collection of data 
traces we shed as we go about our business. As more sensors are put in clothing, homes, 
vehicles, in fact in almost every object, it is possible to capture data on all behaviour. Combine 
that with data captured actively as children volunteer information about their personal 
experience on social media, then one can begin to see that we are in the middle of a data 
revolution. What was once painstakingly and expensively done in the laboratory is now 
accessible as part of the daily life of children.396  
 
Information does not guarantee knowledge. The intellectual task is to explore how both 
passive and actively captured data can be combined in statistical models to predict personal 
outcomes. We have the engineering capability, but we lack the behavioural science that can 
help us look for the right patterns of data and interpret behaviour as meaningful. Children and 
adolescents are, however, generally positive about the use of technology in healthcare and 
expect healthcare to be personalised and relevant. There are ethical considerations to the 
collection, storage, and use of such personal data which needs to be thoughtfully managed 
(e.g.,397. Clinically, in paediatric pain, we might usefully leapfrog current thinking about 




and pencil methods, and instead adapt our assessment to match what is being freely given, 
using media which is capturing experience.  
 
Beyond assessment patients cannot wait for the establishment of evidence bases, likely to 
take a generation to be funded, created, accumulated, and disseminated. Children, throughout 
the developmental spectrum, are in pain now. The evidence-based research that is available 
should be implemented in practice more frequently. To achieve our ambitions in accessibility 
and scale we need more pain clinics that start by being patient focussed, understanding the 
complex, idiosyncratic, and peculiar, personalising pain medicine for each patient. However, 
these centres should aim to be geographically diverse and not consolidate the centralisation 
of specialist pain knowledge identified in Goal 1. Use of technology in this revolution will be 
essential.  
 
In expanding how pain management services are delivered, knowledge re-design should be 
considered. Rather than considering the expert as both the intelligence of the system, the 
means of production, and the quality control process, these functions can be separated.  First, 
we can allow the expert to manage a system of knowledge, including access to technology, 
current evidence, peer support, and technical skills, instead of each individual attempting to 
hold all of the expertise; moving knowledge from the individual to an integrated computerised 
knowledge system. Second, we can enable access to rich curated ‘small’ data on the 
individual, potentially matched with insights from big data on the experience of others, 
supported with evidence from clinical studies. Third, we can liberate the expert from delivery 
by providing multiple local agents in the community with appropriate training to deliver the 
specific intervention under supervision from peers or experts. Ultimately the goal would be to 
shift the location of production, the delivery of assessment and treatment, and the timing of 
the treatment to where and when the patient needs it, rather than where and when we can 
currently manage it (Figure 8).  
 
Figure 8. Redesigning pain services 
 
Conclusion 
This Commission has covered four important goals we believe will advance the field of 
paediatric pain over the next 10 years. We have set out goals and priorities to improve 
research and practice, but it will take the entire research and clinical community, in 
collaboration with funders and policy makers to achieve these goals. It was not possible to 
cover everything in this commission, we have focussed on westernised, economically 
developed countries but recognise that there are different challenges for lower income 
countries (see commentary on lower income countries in this issue). We have not focussed 
much on the importance of experimental research, theoretical development, and the need for 
their closer union.  
 
It is time for change.  We want to ‘make pain matter’ by exposing the social and personal 
forces that traditionally silence pain complaints, put them out of sight, and allow pain 
management to be ignored. There is a long way to go in our study of mechanism(s), to ‘make 
pain understood’ and this will take investment to progress quickly; and support for 
multidisciplinary collaboration will be key to its success. We know how to ‘make pain visible’ 
so we need to develop an intolerance for the absence of assessment and help educate 
everyone working with the child in pain on how to navigate the inferential process of 
determining patient pain status. And ultimately, we need better treatments and better access 
for more people, by making optimal use of technological innovation, and by creating new 
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Box 1. Jeffrey and Jill Lawson and advocacy for pain management  
It was a mother, Jill Lawson, who contributed to one of the most radical changes in 
pain research and pain treatment since Melzack and Wall presented their theory of 
central nervous system plasticity. Her son, Jeffrey Lawson, was born prematurely and 
placed in the care of the Children’s Hospital National Medical Centre in Washington 
DC in the US. Jeffrey underwent extensive surgery without adequate anaesthesia or 
analgesia, because as recent as 1985 the professional belief that infants lacked the 
capability to experience pain was common and prevalent. 5, 6 Although parents, like 
Jill Lawson, often assumed that their infants would be given pain relief during 
surgeries, the medical community were reluctant to provide analgesic and anaesthetic 
agents due to a lack of scientific evidence of the existence of pain in infants, and feared 
adverse effects of the available drugs. Surgery was performed using muscle paralytic 
agents, with a focus on immobilisation to practically facilitate the procedures rather 
than the prevention of suffering.7 Jeffrey lived for five weeks. Jill Lawson’s advocacy 
brought together a combination of science and education to challenge the practice of 
withholding anaesthesia and analgesia in infants because it was thought unnecessary 
or unsafe. By 1995 practices had changed and a UK-based survey of anaesthetists 
demonstrated that 91% now provided systemic opioid analgesia to infants for major 
surgery, whereas in 1988 only 10% of anaesthetists adopted this practice.5 Science is 
not always enough to change practice; public awareness, and policy can take us from 







Box 2: Vaccination pain management: from clinical practice guideline to WHO 
 
Immunization is a global priority to prevent infectious disease. Vaccination involving a 
needle puncture is painful and the pain experienced from vaccinations can cause fear 
and vaccine hesitancy, resulting in future avoidance of vaccinations, which can have 
a huge negative societal impact.   
 
The guideline suggests: 
 
• that for people of all ages, aspiration (pulling back on the syringe to ensure it is 
not in the blood vessel) should not be used during intramuscular injections.32 
• injecting the most painful vaccine last rather than first during visits with more 
than one vaccination.  
• when vaccinating infants and toddlers, breast or formula feeding infants less 
than two years of age or giving them a sugar solution prior to the injection.  
• holding children in one’s arms under the age of three during injections to 
provide them with a sense of comfort.  
• when administering a vaccination to children over the age of three, an upright 
position is recommended as it provides a sense of control and decreases fear.  
• parents of children aged 10 years and under should be present during vaccine 
injections to lower their child’s distress levels, and topical analgesics should be 
applied before injection in children. And,  
• educating parents, older children and adults about what to expect with a 
vaccination and methods to manage any pain.   
 
The guideline culminated in a WHO position paper in 2015 on “Reducing pain at the 
time of vaccination”.33 The position paper was the first policy paper on pain mitigation 
at the time of vaccination, integrating information pertaining to the reduction of pain, 
distress and fear across all age groups. The paper provides important 
acknowledgment from the WHO that: 
 
 “pain during vaccination sessions is manageable and managing pain does not 
decrease the efficacy of the vaccine. There are effective, feasible, non-costly, 
culturally acceptable, and age-specific evidence-based strategies to mitigate pain at 









Table 1: Recent and ongoing initiatives to mobilise knowledge in paediatric pain 
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Box 3: Research and clinical priorities to make pain matter 
 
To make pain experienced by infants, children, and adolescents matter, to make it 
visible, and a response to pain expected and required we believe that research should 
focus on:  
 
1. Improve equity 
a. A person’s pain care should not be determined by non-personal 
determinants of health (e.g. socioeconomic status, age, sex, disability, 
ethnicity). Studies that expose the factors that contribute to inequity in pain 
management, consequences of inequality in pain management, and 
strategies to mitigate inequity are needed. 
b. Effective strategies to make the latest pain management research 
accessible and understandable for patients (e.g. older children and 
adolescents) and their caregivers. 
c. Strategies that ensure that all clinicians involved in the healthcare of a 
child/adolescent are competent to provide pain care within their scope of 
practice. 
 
2. Mitigate Stigma 
a. Consider labels given to pain that cannot be diagnosed with a known 
condition.  
b. Determine best communication strategies when talking to children and 
families with pain to communicate understanding, empathy, and treatment 
course.  
 
3. Social Science of Pain. The lives of children, adolescents and their caregivers, 
and thus pain and pain care, are contextually situated within their social 
environment that has both macro and micro levels. 
a. Macro understanding of the societal (e.g. cultural, political, healthcare 
institutions) forces that influence paediatric pain experiences and 
management (e.g. research funding allocation, political agendas that shape 
policy and narratives, understanding of culturally embedded experiences). 
b. Micro understanding of mechanisms and interventions that leverage social 
factors (e.g. family, friends/peers, teachers) to improve the experience of 













Box 4. Pain definition and classifications 
In 2019, a new IASP task force proposed an updated definition of pain as: “an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”, (p.2) 87 with added text to 
recognise that in many circumstances pain could not be verbally mediated: “Verbal 
description is only one of several behaviours to express pain; inability to 
communicate does not negate the possibility that a human or a non-human animal 
experiences pain.” 87. 
 
Pain can be classified or described in multiple ways, some of the most frequently used 
include:  
By somatosensory mechanism: 
• Nociceptive pain: Pain that arises from actual or threatened damage to non-
neural tissue and is due to the activation of nociceptors (pain-detecting nerves). 
It is the mechanism operating in most everyday painful experiences, and when 
it is the result of an injury or damage, it should resolve when healing has 
occurred. In infants, children and throughout development the mechanisms of 
nociceptive pain change with age.    
• Neuropathic pain: Pain caused by a lesion or disease of the somatosensory 
nervous system. When the system that detects pain is itself damaged although 
it may not respond to a previously painful stimulus (anaesthesia), it may also 
generate pain. Cellular and molecular mechanisms operating when there is 
neuropathic pain are different from nociceptive pain and less likely to resolve 
with the healing process. During development and maturation the mechanisms 
and clinical presentations of neuropathic pain differ with age and underlying 
cause of damage.      
• Nociplastic pain: Pain that arises from altered nociception despite no clear 
evidence of actual or threatened tissue damage causing the activation of 
peripheral nociceptors or evidence for disease or lesion of the somatosensory 
system causing the pain. Changes in nociceptive processing mechanisms can 
be demonstrated in some individuals where a clear underlying cause is not 
detectable by currently available methods.  
 
By time  
• Acute pain: duration less than 3 months 
e.g. acute postoperative pain, vaccination pain.  
Mechanisms operating in acute pain are mostly nociceptive and 
resolution is normally expected when healing occurs. 
• Chronic pain: pain that lasts or recurs for longer than 3 months. 
e.g. chronic musculoskeletal pain, chronic disease-related pain. Chronic 
pain may involve nociceptive, neuropathic and/or nociplastic 
mechanisms.   
In clinical situations pain may also be described as continuous (background pain), or 
intermittent (episodic pain) that is either predictable (incident), or unpredictable 
(spontaneous).  
 
By context or location 
• Disease-related: pain in association with specific diagnoses or conditions  
o e.g.: juvenile inflammatory arthritis (JIA); cancer pain 




o e.g.: visceral; musculoskeletal (bone and/or joint and/or muscle); 
headache; pelvic pain  
• Iatrogenic: pain associated with or following medical treatments  
o e.g.: procedure pain including vaccination, surgical or medical (e.g. 
chemotherapy-induced neuropathy) interventions 
• Idiopathic (or sometimes ‘Functional’ or ‘Primary’): no clear cause identified 
o e.g. chronic primary abdominal pain (see Panel 2 for ICD-11 
terminology). 
When pain is described in terms of context mechanisms may be nociceptive, 





Box 5. Research and clinical priorities to make pain understood 
 
i) Promotion of greater understanding of the subjective nature of pain and the 
multiple and varied inputs at different stages of development that influence 
nociception and the pain response with abandonment of concepts that negate the 
explicit integration of biological, psychological, and social elements that comprise 
all forms of pain.  
ii) Research and clinical understanding of pain to include the whole biopsychosocial 
model, eliminating suggestions of dualism. 
iii) Greater understanding of the early experience of pain on later development and 
behaviour. 
iv) Further development of methodologies to provide robust surrogate pain measures 
in immature and/or non-verbal populations. 
v) Clearer understanding of the factors contributing to and mechanisms playing a role 
in individual variability in pain perception, somatosensory function, development 
and persistence of sensitisation processes, transition to chronic pain and 
responses to treatments.  
vi) Longitudinal studies tracking individual development and how biological, 
environmental, psychological and social factors affect normal developmental 
trajectories, including effects on sensory and affective components of pain 





Box 6. Developmentally appropriate pain intensity assessment methods for children 
six years and older 
 
There are a wide range of pain assessments available to researchers and clinicians 
alike, interested in assessing pain intensity in children across the developmental 
lifespan. In a recent systematic review,238 60 separate pain intensity assessments 
were identified. Not only are there many different measures, but there are also different 
anchors for scales such as the numerical rating scale (NRS) and visual analogue scale 
(VAS). There must also be an understanding of whether the participant or patient can 
understand and interpret the scale, providing a reliable response.  
 
In the latest review of the evidence for pain intensity scales, recommendations for and 
against scales were provided.238 Recommendations were either strong or weak, for or 
against measures. For children with acute pain, strong recommendations for the use 
of the NRS using an 11-point scale from 0 (no hurt) to 10 (the worst hurt you could 
ever imagine), in children 6 years and older. The Faces Pain Scale-Revised was 
strongly recommended for children aged 7 and older, and the Colour Analogue Scale 
was strongly recommended in children 8 years and older. No other strong 
recommendations were provided for other pain intensity scales for acute, post-
operative, or chronic pain. However, VAS and NRS scales are recommended (weak 
recommendation) for children six years or older for post-operative and chronic pain, 
































Box 7: Routine assessment questions to help make child pain and its impact visible 
 
• What are your concerns/worries about your pain? 
• What is a typical day like for you when you have pain? 
• What are the things you do that make your pain better, and things you do that 
make your pain worse? 
• What would you be doing differently if your pain was lessened? 
• How would you know that a pain treatment was working for you? What would 
be a meaningful change to you? 





Box 8: Research and clinical priorities to make pain visible 
 
• Assess pain in every child with an acute or chronic condition that is causing 
pain regardless of age, ability, or sex.  
• Ask all children and parents about the impact of pain on their daily lives. 
Integrate the context of pain measurement by expanding research on social 
and environmental factors that influence pain assessment. 
• Develop measures from a ‘bottom-up’ manner and provide children and parents 
a voice in determining relevant outcome measures and whether pain treatment 
achieves a clinically meaningful change. 
• Use person-centred approaches in pain assessment to help match patients with 
the level of care needed to optimally address pain and comorbidities. 
• Expand the potential of daily life assessments and wearable sensors for both 





Box 9: Research and clinical priorities to make pain better 
 
• Establish a systematic evidence base for pharmacological interventions in 
children with chronic pain, in a creative way. Creative solutions in trial design 
when the randomised controlled trial is not ethical or practical. 
• Develop ways to improve treatments we have, such as through the 
pharmacokinetic and pharmacodynamic properties of analgesics. This could 
include tailoring treatments for other children with pain and also attempt to 
personalise treatments based on known covariates that includes 
pharmacogenomics  
• Establish evidence on how and when to treat children with acute pain to prevent 
transition to chronic pain. Development of interventions that are effective in 
providing coping skills to prevent the onset of long-term pain are critical. 
• Stop trials in areas where there is sufficient evidence, and further evidence will 
not change the quality or confidence in the estimate of effect. Start trials for 
complex patients and to prevent onset of long-term pain.  
• Address complexity boldly and create and test treatments to meet the needs of 








Box 10: Priorities for policy makers and funders 
 
• National level initiatives should be taken to measure pain and its impact in 
large-scale monitors or survey (each country has their own health survey, 
but pain does not have a prominent place). Ideally, same measures across 
countries, to allow cross-national comparisons.  
• Pain service provision and specialism should not only be available in 
urbanised locations. Greater emphasis should be given to providing 
community healthcare professionals with remote access to centralised 
services and knowledge to treat children with pain.  
• Strategies/intervention to increase the accountability for improved pain 
curriculum to prepare healthcare students for clinical practice (e.g.  
accreditation bodies, universities) and plan to increase knowledge and 
competences about pain in children in care providers. Ensure that training 
and resources are prioritised and provided for frontline staff in order to 
prevent unnecessary pain.  
• Knowledge mobilisations initiatives to reduce the gap between evidence to 
practice.  
• Plan and provide funding for multidisciplinary and multi-professional pain 
management services for children in a way similar to what is already the 
case for adults.  
• Develop leadership including partners from diverse sectors (policy, medicine, 
research, pharma, etc) come together to raise awareness and develop 
solutions to address treating paediatric pain. Policy makers, clinicians 
and researchers must unite in a formal way.  
• Introduce institutional commitment initiatives concerning prevention, 
diagnostics and treatment of pain in children in all hospitals. 
• Strategies and interventions to increase the accountability of healthcare 
administrators and clinicians in providing pain care to infants, children, and 
adolescents (e.g. professional regulators, hospital accreditation associations, 
inadequate pain management as a patient safety issue). 
• Ensure the creation of systems that allow for the full participation of patient 








Figure 1. Common types of pain during childhood 
 
 
Figure 2 Pain mechanisms and sources of pain 
Pain can be broadly classified as due to nociceptive, neuropathic or nociplastic, with 
combinations of these mechanisms present in association with different forms of injury 
or illness. Afferent activity in the peripheral nervous system can be generated by 
different sources of pain and is transmitted to the spinal cord where significant 
modulation occurs. Ascending pain pathways reach the brainstem and brain-where 
pain is perceived, and descending pathways also modulate (inhibit or facilitate) 
sensitivity in the spinal cord. 
 
Key: 
* presence of significant developmental changes in structure and/or function 
--- mechanism sometimes involved  
 
Abbreviations: PAG, periaqueductal grey; PBN, parabrachial nucleus; LC, locus 
coruleus; RVM, rostroventral medulla  
 
 
Figure 3 Brain networks in nociceptive (acute) and chronic pain 
Upper images: Pain activates a variety of brain regions that subserve both the sensory 
(i.e. major ascending afferent nociceptive pathways) aspects of pain, and the 
emotional aspects of pain experience.95, 96   
 
Lower image: a- f, structural and functional changes associated with chronic pain. 
 
Abbreviations: ACC, anterior cingulate cortex; AMY, amygdala; BG, basal ganglia; M1,  
primary motor cortex; PAG, periaqueductal grey; PFC, prefrontal cortex; S1, primary 
somatosensory cortex; S2, secondary somatosensory cortex 
 
 
Figure 4. Potential Mechanisms Contributing to susceptibility to Paediatric Chronic 
Pain 
A. Pain Drivers including inductors of pain A1 and resiliency factors A2 impact and 
predict objective pain measures (red).  
B. Disease & C. Disease Severity factors are influenced by both peripheral factors 
(B1-B3) and central factors (B4-B8) that can be either inductors of pain or protective 
against the development of chronic pain.  
 
D. Brain Changes, which can include assessment of (1) functional – using resting 
state measures (RSN) (D1) and structural (D2) – gray matter volume (unpublished 
data from our group).  
E. Psychophysical Changes- Quantitative Sensory Testing (QST) can be used to 
produce measures of ongoing Peripheral Nervous System (PNS) and Central Nervous 
System (CNS) Sensitization (E1-E2).  
Offset Analgesia (OA) (E3) can be used for measures of CNS Modulatory Responsivity 




including rapid and large decrease in pain levels with a small decrease in pain 
stimulus, and Disrupted OA (E3B in males vs. female volunteers ages 20-80 years), 
including minimal decrease in pain levels with a small decrease in pain stimulus). 
Responses for both E3A & E3B are percentage of peak response. 147 
 
Acknowledgement: Figure adapted from a figure conceptualized by David Borsook 
and Christine Sieberg.146 
 
Figure 5. Assessing pain in infants 
Figure taken from 251.  
 
Figure 6. Determining correct dose in a target concentration analgesic strategy 
 
 
Figure 7: A concentration-response relationship for ibuprofen and diclofenac, 
determined for acute pain after tonsillectomy 
The response curve is described using the Hill equation. Maximum effect (EMAX) is 
similar for both drugs. A reduction of 4 pain units correlates with a concentration of 6 
mg/L for both drugs. 
 
A target effect of 4 pain units (VAS 0-10) in which a score above 4 is usually 
considered as pain correlates with a target concentration of 5.8 mg/L for both 
diclofenac and ibuprofen. Pharmacokinetic knowledge can then be used to estimate 
the dose that will achieve that target concentration in an individual361 and be used as 
the starting point of in vitro trial design determining the optimal dosage beforehand. 
 
 
Figure 8. Redesigning pain services 
 
 
 
